

CITATION REPORT

List of articles citing

Biomarkers of cardiovascular disease: molecular basis and practical considerations

DOI: 10.1161/circulationaha.104.482570
Circulation, 2006, 113, 2335-62.

Source: <https://exaly.com/paper-pdf/39528261/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 966 | Translational Science in Medicine. 2006 , 20, 303-310 | | 9 |
| 965 | The ideal model in atherosclerosis and dyslipidaemia - does it exist?. 2006 , 1, 507-11 | | 2 |
| 964 | Integrating Soluble Biomarkers and Imaging Technologies in the Identification of Vulnerable Atherosclerotic Patients. 2006 , 1, 117727190600100 | | 1 |
| 963 | Association of decreased variation of R-R interval and elevated serum C-reactive protein level in a general population in Japan. 2006 , 47, 867-76 | | 29 |
| 962 | Bibliography. Current world literature. Therapy and clinical trials. 2006 , 17, 667-90 | | |
| 961 | Neurohormonal modulation in heart failure of ischemic etiology: correlates with left ventricular remodeling. <i>Current Heart Failure Reports</i> , 2006 , 3, 157-63 | 2.8 | 4 |
| 960 | Risk stratification in secondary prevention: advances in multimarker profiles, or back to basics?. <i>Circulation</i> , 2006 , 114, 184-6 | 16.7 | 10 |
| 959 | Is erectile dysfunction a low-grade systemic inflammatory condition?: reply. 2006 , 28, 643-644 | | |
| 958 | Is erectile dysfunction a low-grade systemic inflammatory condition?. 2007 , 28, 642-3; author reply 643-4 | | 6 |
| 957 | Discontinued drugs in 2005: cardiovascular drugs. 2006 , 15, 1299-308 | | 1 |
| 956 | Arterial aging: pathophysiological principles. 2007 , 12, 329-41 | | 212 |
| 955 | Functional specifications of an integrated proteomics information management and analysis platform. 2007 , 2007, 6065-9 | | 1 |
| 954 | Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. 2007 , 53, 874-81 | | 81 |
| 953 | Cardiovascular biomarkers: added value with an integrated approach?. <i>Circulation</i> , 2007 , 116, 3-5 | 16.7 | 33 |
| 952 | Methods for evaluating endothelial function in humans. 2007 , 49, 748-60 | | 103 |
| 951 | Central blood pressure measurements and antihypertensive therapy: a consensus document. 2007 , 50, 154-60 | | 514 |
| 950 | Can biomarkers improve prediction of future cardiovascular events in patients with cardiovascular disease?. 2007 , 4, 14-5 | | |

| | | | |
|-----|--|------|-----|
| 949 | Vulnerable plaque versus vulnerable patient: emerging blood biomarkers for risk stratification. 2007, 7, 195-201 | | 4 |
| 948 | Risikostratifizierung und (Sekundär-)Prävention der Atherothrombose bei Gefäßpatienten - Screening auf PAVK signalisiert kardio- und zerebrovaskuläres Risiko. 2007, 33, 184-189 | | |
| 947 | Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. 2007, 7, 511-7 | | 49 |
| 946 | Biomarkers and the design of clinical trials in cancer. <i>Biomarkers in Medicine</i> , 2007, 1, 387-97 | 2.3 | 6 |
| 945 | Early detection of acute coronary syndromes and risk stratification by multimarker analysis. <i>Biomarkers in Medicine</i> , 2007, 1, 45-57 | 2.3 | 12 |
| 944 | Non-traditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ?. 2007, 9, 197-206 | | 7 |
| 943 | The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. 2007, 48, 1637-46 | | 60 |
| 942 | C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). <i>Circulation</i> , 2007, 115, 981-9 | 16.7 | 100 |
| 941 | Application of leukocyte transcriptomes to assess systemic consequences of risk factors for cardiovascular disease. 2007, 45, 1109-20 | | 14 |
| 940 | Review: Biomarkers in clinical trials and drug development: measurement of cardiometabolic risk. 2007, 7, 101-106 | | 8 |
| 939 | The Potential of Blood-Based Gene Profiling for Disease Assessment. 277-299 | | |
| 938 | Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease?. 2007, 16, 506-11 | | 13 |
| 937 | Current world literature. Lipid metabolism. 2007, 18, 333-69 | | |
| 936 | Bibliography. Current world literature. Atherosclerosis: cell biology and lipoproteins. 2007, 18, 574-92 | | |
| 935 | Bibliography. Current world literature. Assessment of nutritional status and analytical methods. 2007, 10, 639-49 | | |
| 934 | Bibliography. Current world literature. Genetics and molecular biology. 2007, 18, 199-221 | | |
| 933 | Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. 2007, 153, 881-8 | | 66 |
| 932 | Biomarkers: anatomical and physiological. 2007, 20, 467-8 | | 1 |

| | | | |
|-----|---|-----|------|
| 931 | New biochemical markers: from bench to bedside. 2007 , 381, 14-20 | | 15 |
| 930 | Diagnostic value of carotid intima-media thickness in indicating multi-level atherosclerosis. <i>Atherosclerosis</i> , 2007 , 193, 395-400 | 3.1 | 28 |
| 929 | Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. 2007 , 23, 21-45 | | 110 |
| 928 | Evaluating the role of biomarkers for cardiovascular risk prediction: focus on CRP, BNP and urinary microalbumin. 2007 , 7, 793-804 | | 22 |
| 927 | Proteomics in atherothrombosis: a future perspective. 2007 , 4, 249-60 | | 13 |
| 926 | Discontinued drugs in 2006: cardiovascular drugs translational medicine perspective. 2007 , 16, 1315-26 | | 2 |
| 925 | Biomarkers of atherosclerotic plaque instability and rupture. 2007 , 27, 15-26 | | 298 |
| 924 | Assessing the clinical utility of biomarkers in medicine. <i>Biomarkers in Medicine</i> , 2007 , 1, 419-36 | 2.3 | 29 |
| 923 | [Metalloproteases, vascular remodeling and atherothrombotic syndromes]. 2007 , 60, 959-67 | | 26 |
| 922 | Mechanical factors in arterial aging: a clinical perspective. 2007 , 50, 1-13 | | 1640 |
| 921 | Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. 2007 , 50, 205-14 | | 177 |
| 920 | Emerging paradigms, platforms, and unifying themes in biomarker science. 2007 , 50, 1777-80 | | 10 |
| 919 | Individual assessment of arteriosclerosis by empiric clinical profiling. 2007 , 2, e1215 | | 2 |
| 918 | . 2007 , | | 2 |
| 917 | Increased serum levels of C-reactive protein and matrix metalloproteinase-9 in obstructive sleep apnea syndrome. 2007 , 120, 1482-1486 | | 31 |
| 916 | Sandwich-type, antibody microarrays for the detection and quantification of cardiovascular risk markers. 2007 , 125, 581-588 | | 25 |
| 915 | HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids. 2007 , 851, 21-9 | | 110 |
| 914 | Genome-wide association with select biomarker traits in the Framingham Heart Study. 2007 , 8 Suppl 1, S11 | | 94 |

| | | |
|-----|---|-----|
| 913 | Clinical proteomics: A need to define the field and to begin to set adequate standards. 2007 , 1, 148-56 | 237 |
| 912 | Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools. 2007 , 261, 214-34 | 27 |
| 911 | Microalbuminuria screening in patients with hypertension: recommendations for clinical practice. 2008 , 62, 97-108 | 30 |
| 910 | Role of C-reactive protein in coronary risk reduction: focus on primary prevention. 2007 , 99, 718-25 | 35 |
| 909 | Proteomics in cardiovascular surgery. 2007 , 133, 210-4 | 21 |
| 908 | Kardio- und zerebrovaskuläres Risiko bei PAVK. 2007 , 2, IV22-IV29 | |
| 907 | Makroangiopathie bei Diabetes mellitus. 2008 , 3, 29-34 | |
| 906 | Cardiac troponins. 2008 , 18, 235-245 | 83 |
| 905 | Circulating serum adiponectin levels in patients with coronary artery disease: relationship to atherosclerotic burden and cardiac function. 2008 , 264, 593-8 | 28 |
| 904 | Risk stratification and prognostic factors in the post-myocardial infarction patient. 2008 , 102, 13G-20G | 11 |
| 903 | Risk factors for failure of lower-extremity revascularization procedures: are they different for bypass and percutaneous procedures?. 2008 , 21, 143-53 | 15 |
| 902 | Dyslipidemia in youth with diabetes: to treat or not to treat?. 2008 , 153, 458-65 | 39 |
| 901 | Proteomics as a tool for the modelling of biological processes and biomarker development in nutrition research. 2008 , 99 Suppl 3, S66-71 | 44 |
| 900 | Technology Insight: biomarker development in acute kidney injury--what can we anticipate?. 2008 , 4, 154-65 | 52 |
| 899 | Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. 2008 , 51, 627-33 | 161 |
| 898 | An overview of cardiac systems biology. 2008 , 44, 460-9 | 15 |
| 897 | Severity dependent increases in circulating cardiac troponin I and MMP-9 concentrations after experimental acute pulmonary thromboembolism. 2008 , 388, 184-8 | 17 |
| 896 | Angiotensin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. 2008 , 40, 215-22 | 49 |

| | | |
|-----|--|-----|
| 895 | Elevated angiogenin levels in chronic heart failure. 2008 , 40, 474-9 | 19 |
| 894 | New cardiovascular risk markers: the race is on, but are there any winners?. 2008 , 68, 673-7 | 2 |
| 893 | High-performance immunoassays based on through-stencil patterned antibodies and capillary systems. 2008 , 80, 1763-9 | 39 |
| 892 | A systematic review of epidemiological associations between low and moderate doses of ionizing radiation and late cardiovascular effects, and their possible mechanisms. 2008 , 169, 99-109 | 141 |
| 891 | Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). 2008 , 12, R45 | 29 |
| 890 | Protein C as a surrogate end-point for clinical trials of sepsis. 2008 , 12, 139 | 1 |
| 889 | Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice. 2008 , 46, 748-63 | 35 |
| 888 | Distribution of plasma cardiac troponin I values in healthy subjects: pathophysiological considerations. 2008 , 46, 804-8 | 47 |
| 887 | Natriuretic peptide testing in primary care patients. 2008 , 46, 1533-42 | 2 |
| 886 | Metabonomics study of intestinal transplantation using ultrahigh-performance liquid chromatography time-of-flight mass spectrometry. 2008 , 77, 122-30 | 7 |
| 885 | The use of high-sensitivity assays for C-reactive protein in clinical practice. 2008 , 5, 621-35 | 95 |
| 884 | Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. 2008 , 39, 2902-9 | 128 |
| 883 | Use of cardiac biomarkers in end-stage renal disease. 2008 , 19, 1643-52 | 144 |
| 882 | Metabolomics: A Global Biochemical Approach to the Discovery of Biomarkers for Psychiatric Disorders. 2008 , 129-162 | 1 |
| 881 | Progressing from risk factors to omics. 2008 , 1, 141-6 | 18 |
| 880 | Variability of serial lipoprotein-associated phospholipase A2 measurements in post myocardial infarction patients: results from the AIRGENE Study Center Augsburg. 2008 , 54, 124-30 | 20 |
| 879 | Recent advances in atherosclerosis-based proteomics: new biomarkers and a future perspective. 2008 , 5, 679-91 | 32 |
| 878 | Biochemical markers of myocardial remodelling in hypertensive heart disease. 2009 , 81, 509-18 | 57 |

| | | | |
|-----|---|-----|-----|
| 877 | Genetics of the Framingham Heart Study population. 2008 , 62, 33-65 | | 66 |
| 876 | Proteomic analysis of human plasma and blood cells in nutritional studies: development of biomarkers to aid disease prevention. 2008 , 5, 819-26 | | 20 |
| 875 | Natriuretic Peptides and Inflammatory Markers for Risk Stratification in Patients with Ischemic Heart Disease. 53-74 | | 0 |
| 874 | Novel Markers in Patients with Suspected Acute Coronary Syndromes. 75-92 | | |
| 873 | Candidate circulating biomarkers for the cardiovascular disease continuum. 2008 , 14, 2445-61 | | 11 |
| 872 | . 2008 , | | 1 |
| 871 | CARDIOVASCULAR RISK IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE ROLE OF SYSTEMIC INFLAMMATION AND ENDOTHELIAL DYSFUNCTION. 2008 , 4, 71-76 | | 1 |
| 870 | Proteomic Biomarkers of Atherosclerosis. 2008 , 3, 101-113 | | 21 |
| 869 | Characteristics and Causes of Immune Dysfunction Related to Uremia and Dialysis. 2008 , 28, 183-187 | | 120 |
| 868 | A new curriculum to link the basic science of aging with geriatric practice. 2009 , 52, 355-63 | | 2 |
| 867 | Imaging Tools in Cardiovascular Research. 2009 , 105-121 | | |
| 866 | Biomarker discovery in neurological diseases: a metabolomic approach. 2009 , Volume 1, 27-41 | | 1 |
| 865 | Assessment of platelets and the endothelium in patients presenting with acute coronary syndromes--is there a future?. 2009 , 102, 1144-8 | | 12 |
| 864 | Use of Obesity Biomarkers in Cardiovascular Epidemiology. <i>Disease Markers</i> , 2009 , 26, 247-263 | 3.2 | 20 |
| 863 | Red blood cell fatty acid patterns and acute coronary syndrome. 2009 , 4, e5444 | | 45 |
| 862 | Isolation of high density lipoprotein subclasses by electrofiltration and their chemical components. 2009 , 39, 248-65 | | 3 |
| 861 | The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. 2009 , 20, 97-104 | | 36 |
| 860 | The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. 2009 , 55, 219-28 | | 73 |

| | | | |
|-----|---|------|-----|
| 859 | The ankle-brachial index as a biomarker of cardiovascular risk: it's not just about the legs. <i>Circulation</i> , 2009 , 120, 2033-5 | 16.7 | 28 |
| 858 | Computational biology for cardiovascular biomarker discovery. 2009 , 10, 367-77 | | 28 |
| 857 | Chapter 1 High-Sensitivity Troponin. 2009 , 1-30 | | 33 |
| 856 | ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American Association of Cardiovascular and Pulmonary Rehabilitation; American Association of Cardiovascular and Pulmonary Rehabilitation. <i>Circulation</i> , 2009 , 120, e100-26 | 16.7 | 21 |
| 855 | Multiscale Nanoporous Structures for Sensing and Diagnostics. 2009 , 1236, 1 | | |
| 854 | Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. 2009 , 38, 217-31 | | 171 |
| 853 | Commentary: C-reactive protein and risk prediction--moving beyond associations to assessing predictive utility and clinical usefulness. 2009 , 38, 231-4 | | 5 |
| 852 | Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. <i>Circulation</i> , 2009 , 119, 2396-404 | 16.7 | 71 |
| 851 | Nutrition proteomics and biomarker discovery. 2009 , 6, 349-51 | | 10 |
| 850 | G-protein-coupled receptor kinases in cardiovascular conditions: focus on G-protein-coupled receptor kinase 2, a gain in translational medicine. <i>Biomarkers in Medicine</i> , 2009 , 3, 525-40 | 2.3 | 5 |
| 849 | Gene expression profiles in peripheral blood mononuclear cells of chronic heart failure patients. 2009 , 38, 233-40 | | 44 |
| 848 | Assessment of the multiple-biomarker approach for diagnosis of myocardial infarction in patients presenting with symptoms suggestive of acute coronary syndrome. 2009 , 55, 93-100 | | 54 |
| 847 | Soluble forms of RAGE in human diseases: clinical and therapeutical implications. 2009 , 16, 940-52 | | 140 |
| 846 | Tracking biocultural pathways in population health: the value of biomarkers. 2009 , 36, 281-97 | | 67 |
| 845 | Old and new biomarkers of heart failure. 2009 , 11, 331-5 | | 65 |
| 844 | Is hsCRP Back on Board? Implications from the JUPITER Trial. 2009 , 55, 216-8 | | 10 |
| 843 | Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. 2009 , 302, 49-57 | | 411 |
| 842 | The impact of ezetimibe on endothelial function and other markers of cardiovascular risk. 2009 , 43, 2021-30 | | 11 |

| | | | |
|-----|--|-----|-----|
| 841 | Smoking and atherosclerotic cardiovascular disease: part II: role of cigarette smoking in cardiovascular disease development. <i>Biomarkers in Medicine</i> , 2009 , 3, 617-53 | 2.3 | 29 |
| 840 | ERS Meeting Report. Metabolic aspects of obstructive sleep apnoea syndrome. 2009 , 18, 113-24 | | 26 |
| 839 | Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. 2009 , 35, 165-76 | | 215 |
| 838 | Assessment of endothelial function using digital pulse amplitude tonometry. 2009 , 19, 6-11 | | 130 |
| 837 | What is the optimum perioperative drug therapy following lower-extremity vein bypass surgery?. 2009 , 22, 245-51 | | 3 |
| 836 | Biological markers in inflammatory bowel disease: practical consideration for clinicians. 2009 , 33 Suppl 3, S158-73 | | 83 |
| 835 | Proteomic analysis reveals significant elevation of heat shock protein 70 in patients with chronic heart failure due to arrhythmogenic right ventricular cardiomyopathy. 2009 , 332, 103-11 | | 31 |
| 834 | Moving toward new statin guidelines in a post-JUPITER world: principles to consider. 2009 , 11, 249-56 | | 17 |
| 833 | Riboflavin supplementation and biomarkers of cardiovascular disease in the elderly. 2009 , 13, 441-6 | | 14 |
| 832 | Cardiac markers: a clear cause for point-of-care testing. 2009 , 393, 1453-62 | | 54 |
| 831 | Plasma fingerprinting with GC-MS in acute coronary syndrome. 2009 , 394, 1517-24 | | 74 |
| 830 | Synthesis analysis of regression models with a continuous outcome. 2009 , 28, 1620-35 | | 7 |
| 829 | Point of care measurement of plasma creatinine in critically ill patients with acute kidney injury. 2009 , 64, 403-7 | | 30 |
| 828 | The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats. 2009 , 30, 935-46 | | 36 |
| 827 | Non-invasive model-based estimation of aortic pulse pressure using suprasystolic brachial pressure waveforms. 2009 , 42, 2111-5 | | 54 |
| 826 | Circulating sTWEAK improves the prediction of coronary artery disease. 2009 , 42, 1381-6 | | 32 |
| 825 | Ultrasound lung comets in systemic sclerosis: a chest sonography hallmark of pulmonary interstitial fibrosis. 2009 , 48, 1382-7 | | 152 |
| 824 | Ischemia modified albumin, high-sensitivity c-reactive protein and natriuretic peptide in patients with coronary atherosclerosis. 2009 , 408, 65-9 | | 22 |

| | | | |
|-----|---|-----|------|
| 823 | Circulating cell-free DNA levels in plasma increase with severity in experimental acute pulmonary thromboembolism. 2009 , 409, 112-6 | | 26 |
| 822 | Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation. 2009 , 123, 617-21 | | 18 |
| 821 | Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. 2009 , 46, 142-8 | | 46 |
| 820 | Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. 2009 , 136, 80-5 | | 45 |
| 819 | Irritable bowel syndrome: towards biomarker identification. 2009 , 15, 478-89 | | 141 |
| 818 | ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease), developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Technology, America. 2009 , 54, 1336-63 | | 44 |
| 817 | Nuevos marcadores en el síndrome coronario agudo. 2009 , 2, 34-46 | | |
| 816 | New Ultrasound Technologies for Quantitative Assessment of Left Ventricular Function. 2009 , 319-342 | | |
| 815 | Endothelial Function in the Stress Echocardiography Laboratory. 2009 , 375-392 | | |
| 814 | Cardiovascular proteomics: implications for clinical applications. 2009 , 29, 87-99 | | 14 |
| 813 | Neopterin predicts the risk for fatal ischemic heart disease in type 2 diabetes mellitus: long-term follow-up of the HUNT 1 study. <i>Atherosclerosis</i> , 2009 , 207, 239-44 | 3-1 | 33 |
| 812 | The Krebs cycle and mitochondrial mass are early victims of endothelial dysfunction: proteomic approach. 2009 , 174, 34-43 | | 82 |
| 811 | How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. 2009 , 85, 538-45 | | 92 |
| 810 | Inflammation in atherosclerosis: from pathophysiology to practice. 2009 , 54, 2129-38 | | 1415 |
| 809 | Blood protein signature for the early diagnosis of Alzheimer disease. 2009 , 66, 161-5 | | 39 |
| 808 | Emerging inflammatory biomarkers with acute stroke. 2009 , 21, 493-505 | | 5 |
| 807 | Nuts and novel biomarkers of cardiovascular disease. 2009 , 89, 1649S-56S | | 193 |
| 806 | New and emerging biomarkers of heart failure. 2009 , 46, 107-28 | | 11 |

| | | |
|-----|---|-----|
| 805 | New statistical methods for the evaluation of cardiovascular risk markers: what the clinician should know. 2009 , 117, 13-5 | 6 |
| 804 | Imaging and laboratory biomarkers in cardiovascular disease. 2009 , 15, 1131-41 | 7 |
| 803 | Inflammatory systemic biomarkers in setting acute coronary syndromes--effects of the diurnal variation. 2009 , 10, 1001-8 | 43 |
| 802 | Is there any additional prognostic value of central blood pressure wave forms beyond peripheral blood pressure?. 2009 , 15, 254-66 | 18 |
| 801 | Faecal calprotectin in term and preterm neonates. 2010 , 51, 542-7 | 57 |
| 800 | High-density lipoprotein quantity or quality for cardiovascular prevention?. 2010 , 16, 1494-503 | 28 |
| 799 | Novel systemic cardiovascular disease biomarkers. 2010 , 10, 180-205 | 18 |
| 798 | Role of biomarkers in predicting CVD risk in the setting of HIV infection?. 2010 , 5, 467-72 | 13 |
| 797 | In Search of Biomarkers for Drug-Induced Vascular Injury. 2010 , 279-305 | 1 |
| 796 | Placental growth factor as short-term predicting biomarker in acute coronary syndrome patients with non-ST elevation myocardial infarction. 2010 , 103, 982-7 | 6 |
| 795 | Heart failure, chronic kidney disease, and biomarkers--an integrated viewpoint--. 2010 , 74, 1274-82 | 64 |
| 794 | Atherosclerosis and sex hormones: current concepts. 2010 , 119, 493-513 | 74 |
| 793 | Two-step on-particle ionization/enrichment via a washing- and separation-free approach: multifunctional TiO ₂ nanoparticles as desalting, accelerating, and affinity probes for microwave-assisted tryptic digestion of phosphoproteins in ESI-MS and MALDI-MS: comparison with microscale TiO ₂ . 2010 , 396, 2909-19 | 30 |
| 792 | Review and meta-analysis of epidemiological associations between low/moderate doses of ionizing radiation and circulatory disease risks, and their possible mechanisms. 2010 , 49, 139-53 | 109 |
| 791 | Left ventricular hypertrophy induced by abdominal aortic banding and its prevention by angiotensin receptor blocker telmisartan--a proteomic analysis. 2010 , 66, 329-38 | 15 |
| 790 | Use of multiple biomarkers in heart failure. 2010 , 12, 230-6 | 11 |
| 789 | Biomarker guided therapy for heart failure: focus on natriuretic peptides. 2010 , 15, 351-70 | 13 |
| 788 | Multi-marker strategies in heart failure: clinical and statistical approaches. 2010 , 15, 343-9 | 23 |

| | | |
|-----|--|------|
| 787 | Introduction: biomarkers in heart failure. 2010 , 15, 249-50 | 1 |
| 786 | Do non-targeted effects increase or decrease low dose risk in relation to the linear-non-threshold (LNT) model?. 2010 , 687, 17-27 | 34 |
| 785 | Biomarkers in acute myocardial infarction. 2010 , 8, 34 | 142 |
| 784 | Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. 2010 , 13, 36-41 | 139 |
| 783 | A multimarker approach for the prediction of coronary artery disease: cost-effectiveness analysis. 2010 , 13, 770-7 | 6 |
| 782 | New features of troponin testing in different clinical settings. 2010 , 268, 207-17 | 26 |
| 781 | . 2010 , | 7 |
| 780 | . 2010 , | 15 |
| 779 | . 2010 , | 4 |
| 778 | Application of Proteomics in Nutrition Research. 2010 , 213-223 | 2 |
| 777 | Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction. 2010 , 3, 436-44 | 56 |
| 776 | Testicular cancer survivorship: research strategies and recommendations. 2010 , 102, 1114-30 | 215 |
| 775 | Serum gamma-glutamyl transferase and risk of heart failure in the community. 2010 , 30, 1855-60 | 66 |
| 774 | Chromogranin B in heart failure: a putative cardiac biomarker expressed in the failing myocardium. 2010 , 3, 503-11 | 31 |
| 773 | Arterial stiffness and cardiovascular events: the Framingham Heart Study. <i>Circulation</i> , 2010 , 121, 505-11 16.7 | 1473 |
| 772 | A methodological reappraisal of total and high molecular weight adiponectin determination in human peripheral circulation: comparison of four immunometric assays. 2010 , 48, 561-8 | 12 |
| 771 | Biomarkers of cardiovascular risk--matters of prediction and precision. 2010 , 48, 1683-4 | |
| 770 | Multiple cytokine biomarkers in heart failure. 2010 , 10, 147-57 | 16 |

| | | | |
|-----|---|------|-----|
| 769 | Primary care research and clinical practice: cardiovascular disease. 2010 , 86, 696-703 | | 6 |
| 768 | Optimal definitions for abdominal obesity and the metabolic syndrome in Andean Hispanics: the PREVENCIÓN study. 2010 , 33, 1385-8 | | 26 |
| 767 | Apolipoproteins in the discrimination of atherosclerotic burden and cardiac function in patients with stable coronary artery disease. 2010 , 12, 254-9 | | 5 |
| 766 | A window into your heart: taking cardiac troponin to the next level. <i>Biomarkers in Medicine</i> , 2010 , 4, 889-94 | | 2 |
| 765 | Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery. 2010 , 340, b5606 | | 27 |
| 764 | Biomarkers of cell damage induced by oxidative stress in Parkinson's disease and related models. 2010 , 10, 278-86 | | 11 |
| 763 | Point-of-care test of heart-type fatty acid-binding protein for the diagnosis of early acute myocardial infarction. 2010 , 31, 307-12 | | 23 |
| 762 | Current developments in salivary diagnostics. <i>Biomarkers in Medicine</i> , 2010 , 4, 171-89 | 2.3 | 242 |
| 761 | Biomarkers for diagnosis in thoracic aortic disease: CON. 2010 , 28, 213-20 | | 3 |
| 760 | References. 203-222 | | |
| 759 | Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. 2010 , 56, 2006-20 | | 177 |
| 758 | Biomarkers to improve the benefit/risk balance for approved therapeutics: a US FDA perspective on personalized medicine. 2010 , 1, 631-41 | | 10 |
| 757 | Weak associations between prognostic biomarkers and disease in preliminary studies illustrates the breach between statistical significance and diagnostic discrimination. 2010 , 411, 467-73 | | 5 |
| 756 | Metabolic syndrome and cardiovascular risk prediction in peripheral arterial disease. 2010 , 20, 676-82 | | 15 |
| 755 | Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. 2010 , 31, 199-205 | | 179 |
| 754 | Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. 2010 , 160, 286-93 | | 52 |
| 753 | Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. <i>Circulation</i> , 2010 , 121, 2388-97 | 16.7 | 257 |
| 752 | Leukocyte count in peripheral arterial disease: A simple, reliable, inexpensive approach to cardiovascular risk prediction. <i>Atherosclerosis</i> , 2010 , 210, 288-93 | 3.1 | 37 |

| | | |
|-----|---|-----|
| 751 | Clinical Pharmacology: Current Topics and Case Studies. 2010 , | |
| 750 | Physiopathologie de la maladie athéro-thrombotique : quelques données fondamentales pour comprendre le risque résiduel. 2010 , 4, 361-368 | |
| 749 | Acute Coronary Syndromes. 2010 , 303-312 | |
| 748 | Heart Failure in the Era of Genomic Medicine. 2010 , 313-325 | |
| 747 | Biomarkers of Cardiac Injury. 2010 , 119-155 | 1 |
| 746 | Cardiac: is this biomarker ready for the prime time?. 2010 , 242, 66-72 | 4 |
| 745 | From multimarker approach to multiplex assays in acute coronary syndromes: what are we searching for?. 2010 , 12, 18-24 | 1 |
| 744 | Clinical evaluation of efficacy and tolerability of HMC05 in healthy subjects with normal and high-normal blood pressure: a pilot study. 2011 , 77, 221-5 | 2 |
| 743 | Papel de la proteína C reactiva en las enfermedades cardiovasculares. 2011 , 18, 273-278 | 5 |
| 742 | Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure. 2011 , 10, 4054-65 | 141 |
| 741 | Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy. 2011 , 7, 323-31 | 25 |
| 740 | Myocardial edema in acute ischemic injury. 2011 , 4, 279-81 | 4 |
| 739 | Development of a novel single sensor multiplexed marker assay. 2011 , 136, 1496-501 | 30 |
| 738 | Usefulness of mid regional pro-atrial natriuretic peptide in the exacerbations of chronic obstructive pulmonary disease. 2011 , 412, 470-5 | 8 |
| 737 | Independent and additive predictive value of total cholesterol content of erythrocyte membranes with regard to coronary artery disease clinical presentation. 2011 , 150, 22-7 | 21 |
| 736 | Myeloperoxidase in the acute coronary syndrome: equal concentrations at any time of day?. 2011 , 150, 206-7 | 3 |
| 735 | Melatonin and myocardial protection. 2011 , 150, 207 | 2 |
| 734 | [Inflammatory biomarkers in the acute coronary syndrome]. 2011 , 136, 461-2; author reply 462 | 0 |

| | | |
|-----|--|-----|
| 733 | [Copper deficiency after bariatric surgery simulating a myelodysplastic syndrome]. 2011 , 136, 460-1 | 1 |
| 732 | [Can we identify biomarkers in bipolar depression? From imaging to biology]. 2011 , 37 Suppl 3, S185-90 | 1 |
| 731 | 25-Hydroxyvitamin D levels in the outpatient population of a northern Italy region. 2011 , 5, 63-66 | |
| 730 | New Noninvasive Modalities in Coronary Angiography - Diagnostic Values of New Biomarkers for Cardiovascular Disease. 2011 , | 1 |
| 729 | Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. 2011 , 343, d6829 | 42 |
| 728 | Epidemiology of Heart Failure. 2011 , 346-354 | |
| 727 | Smoking and hypertension: effects on clinical, biochemical and pathological variables due to isolated or combined action on cardiovascular system. 2011 , 17, 2987-3001 | 17 |
| 726 | What is the role of alternative biomarkers for coronary heart disease?. 2011 , 75, 289-93 | 5 |
| 725 | Hypertension treatment update: focus on direct renin inhibition. 2011 , 23, 239-48 | 10 |
| 724 | Circulating, imaging, and genetic biomarkers in cardiovascular risk prediction. 2011 , 21, 105-12 | 9 |
| 723 | A 1H NMR based metabonomics approach to progression of coronary atherosclerosis in a rabbit model. 2011 , 46, 2240-2247 | 20 |
| 722 | Effect of marine n-3 fatty acids on circulating inflammatory markers in healthy subjects and subjects with cardiovascular risk factors. 2011 , 60, 309-19 | 34 |
| 721 | Blood biomarkers of ischemic stroke. 2011 , 8, 349-60 | 141 |
| 720 | Can haemostatic factors predict atherothrombosis?. 2011 , 6, 497-501 | 16 |
| 719 | The radiation issue in cardiology: the time for action is now. 2011 , 9, 35 | 97 |
| 718 | Variance decomposition of protein profiles from antibody arrays using a longitudinal twin model. 2011 , 9, 73 | 18 |
| 717 | Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques. 2011 , 3, 620-46 | 14 |
| 716 | Lycopene and cardiovascular diseases: an update. 2011 , 18, 1146-63 | 125 |

| | | | |
|-----|---|------|-----|
| 715 | Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions. 2011 , 7, 175-200 | | 28 |
| 714 | The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function. 2011 , 5, 241-73 | | 8 |
| 713 | Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. <i>Circulation</i> , 2011 , 123, 551-65 | 16.7 | 197 |
| 712 | Proteomic biomarkers for diagnosis in acute myocardial infarction. 2011 , 16, 1-11 | | 19 |
| 711 | Comprehensive analysis of protein modifications by top-down mass spectrometry. 2011 , 4, 711 | | 105 |
| 710 | What is a Biomarker? From its Discovery to Clinical Application. 2011 , 30, 186-192 | | 18 |
| 709 | Sustained virological response to interferon- α plus ribavirin decreases inflammation and endothelial dysfunction markers in HIV/HCV co-infected patients. 2011 , 66, 645-9 | | 23 |
| 708 | Prevention of overweight/obesity as a strategy to optimize cardiovascular health. <i>Circulation</i> , 2011 , 124, 840-50 | 16.7 | 53 |
| 707 | Nontraditional risk factors and biomarkers for cardiovascular disease: mechanistic, research, and clinical considerations for youth: a scientific statement from the American Heart Association. <i>Circulation</i> , 2011 , 123, 2749-69 | 16.7 | 227 |
| 706 | Cardiovascular risk and rheumatoid arthritis--the next step: differentiating true soluble biomarkers of cardiovascular risk from surrogate measures of inflammation. 2011 , 50, 1944-54 | | 26 |
| 705 | Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. 2011 , 305, 2200-10 | | 185 |
| 704 | Metabolomics in toxicology: preclinical and clinical applications. 2011 , 120 Suppl 1, S146-70 | | 159 |
| 703 | Childhood obesity and cardiovascular disease: links and prevention strategies. 2011 , 8, 513-25 | | 121 |
| 702 | Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. 2011 , 70, 812-7 | | 83 |
| 701 | Ways of coping and biomarkers of an increased atherothrombotic cardiovascular disease risk in elderly individuals. 2012 , 2012, 875876 | | 12 |
| 700 | Perspectives for metabolomics in testosterone replacement therapy. 2012 , 215, 3-16 | | 4 |
| 699 | Insights into left ventricular remodeling through noninvasive measures of myocardial matrix expansion with cardiovascular magnetic resonance. <i>Circulation</i> , 2012 , 126, 1179-81 | 16.7 | 4 |
| 698 | Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. 2012 , 19, 62-71 | | 19 |

| | | |
|-----|--|-----|
| 697 | Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. 2012 , 27, 3523-31 | 105 |
| 696 | Reply to Chow et al. 2012 , 55, 751-752 | 14 |
| 695 | Plasma biomarkers for prediction of sudden cardiac death: another piece of the risk stratification puzzle?. 2012 , 5, 237-43 | 24 |
| 694 | Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota Heart Survey. 2012 , 58, 930-5 | 49 |
| 693 | Molecular and Translational Vascular Medicine. 2012 , | |
| 692 | Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. 2012 , 110, 658-62 | 51 |
| 691 | Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. 2012 , 2012, 657025 | 53 |
| 690 | Copeptin in mitral balloon valvuloplasty: a new approach in valvular interventions?. 2012 , 121, 194-6 | |
| 689 | Molecular imaging of inflammation for detection of vulnerable atheromatous plaques. 2012 , 33, 1857-60 | 1 |
| 688 | Urinary markers of kidney injury and kidney function decline in HIV-infected women. 2012 , 61, 565-73 | 46 |
| 687 | Lessons learned from the first wave of aging with HIV. 2012 , 26 Suppl 1, S11-8 | 35 |
| 686 | ADME of Cardiovascular Drugs. 2012 , 1 | |
| 685 | Central Blood Pressure and Prediction of Cardiovascular Events. 2012 , 8, 108-113 | 7 |
| 684 | Variability of fibrinogen measurements in post-myocardial infarction patients. Results from the AIRGENE study center Augsburg. 2012 , 107, 895-902 | 2 |
| 683 | Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. 2012 , 26, 2315-26 | 92 |
| 682 | Progress towards identifying biomarkers of vascular aging for total cardiovascular risk prediction. 2012 , 30 Suppl, S19-26 | 17 |
| 681 | Toward a systemic research agenda for addressing the joint epidemics of HIV/AIDS and noncommunicable diseases. 2012 , 26 Suppl 1, S7-10 | 15 |
| 680 | Biomarkers and Their Potential Use in Transplantation. 2012 , 66, 219-268 | |

| | | |
|-----|--|-----|
| 679 | HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. 2012 , 60 Suppl 1, S1-18 | 394 |
| 678 | Normative and criterion-related standards for shuttle run performance in youth. 2012 , 24, 157-69 | 19 |
| 677 | Biomarkers: hopes and challenges in the path from discovery to clinical practice. 2012 , 159, 197-204 | 52 |
| 676 | Cardiovascular genomics: a biomarker identification pipeline. 2012 , 16, 809-22 | 8 |
| 675 | Application of Steroid Hormone Metabolomics in Search of Biomarkers in Clinical Research. 2012 , 73, 381-389 | 10 |
| 674 | The Current Status of Metabolomics in Drug Discovery and Development. 2012 , 73, 535-546 | 9 |
| 673 | Rapid and Sensitive Determination of Five Amine Biomarkers in Plasma Samples from Stroke Patients by MEKC with Precolumn Derivatization. 2012 , 75, 1217-1221 | 2 |
| 672 | RCM: a novel association approach to search for coronary artery disease genetic related metabolites based on SNPs and metabolic network. 2012 , 100, 282-8 | 1 |
| 671 | Nanomedicine for the prevention, treatment and imaging of atherosclerosis. 2012 , 8 Suppl 1, S59-68 | 38 |
| 670 | Marcadores biológicos: ¿qué aportan los péptidos natriuréticos?. 2012 , 29, 57-62 | |
| 669 | Gesundheitsökonomische Forschung im Kontext Individualisierter Medizin [Forschungsethische und datenschutzrechtliche Aspekte am Beispiel des GANI_MED-Projekts. 2012 , 10, 105-121 | 5 |
| 668 | Responsible healthcare innovation: anticipatory governance of nanodiagnostics for theranostics medicine. 2012 , 12, 857-70 | 14 |
| 667 | Release of tissue-specific proteins into coronary perfusate as a model for biomarker discovery in myocardial ischemia/reperfusion injury. 2012 , 11, 2114-26 | 17 |
| 666 | Biomarcadores cardíacos: Presente y futuro. 2012 , 19, 300-311 | 0 |
| 665 | Developing and assessing cardiovascular biomarkers. 2012 , 159, 265-76 | 19 |
| 664 | High serum S100A8/A9 levels and high cardiovascular complication rate in type 2 diabetics with ultrasonographic low carotid plaque density. 2012 , 97, 82-90 | 16 |
| 663 | Noninvasive prediction of left ventricular end-diastolic pressure in patients with coronary artery disease and preserved ejection fraction. 2012 , 28, 80-6 | 4 |
| 662 | No evidence of association between the synonymous polymorphisms in XRCC1 and ERCC2 and breast cancer susceptibility among nonsmoking Chinese. 2012 , 503, 118-22 | 7 |

| | | |
|-----|---|-----|
| 661 | Cancer and non-cancer brain and eye effects of chronic low-dose ionizing radiation exposure. 2012 , 12, 157 | 86 |
| 660 | Identifying novel biomarkers for cardiovascular disease risk prediction. 2012 , 272, 430-9 | 38 |
| 659 | Translation of New Technologies in Biomedicines: Shaping the Road from Basic Research to Drug Development and Clinical Application—and Back Again. 2012 , 113-152 | 1 |
| 658 | Circulating biomarkers. 2012 , 130 Suppl 1, S12-5 | 42 |
| 657 | Oxidative stress is associated with visceral adipose tissue and subclinical atherosclerosis in a healthy multi-ethnic population. 2012 , 37, 1164-70 | 7 |
| 656 | Echocardiography for the "superior doctor": a call to action in the management of heart failure. 2012 , 5, 141-3 | 1 |
| 655 | Methodological and analytic considerations for blood biomarkers. 2012 , 55, 25-33 | 18 |
| 654 | Why are some studies of cardiovascular markers unreliable? The role of measurement variability and what an aspiring clinician scientist can do before it is too late. 2012 , 55, 14-24 | 19 |
| 653 | Nanomedicine for the prevention, treatment and imaging of atherosclerosis. 2012 , 73, 52-60 | 31 |
| 652 | [Cardiac markers in different degrees of chronic kidney disease: influence of inflammation and previous heart disease]. 2012 , 139, 98-102 | 5 |
| 651 | A computational pipeline for the development of multi-marker bio-signature panels and ensemble classifiers. 2012 , 13, 326 | 22 |
| 650 | Biosensors for cardiac biomarkers detection: A review. 2012 , 171-172, 62-76 | 245 |
| 649 | Age is an Important Risk Factor for Type 2 Diabetes Mellitus and Cardiovascular Diseases. 2012 , | 21 |
| 648 | Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer. 2012 , 2, 17-28 | 2 |
| 647 | A multicenter study design to assess the clinical usefulness of semi-automatic measurement of flow-mediated vasodilatation of the brachial artery. 2012 , 53, 170-5 | 43 |
| 646 | Cardiovascular Disease in Great Apes. 2012 , 408-415 | 15 |
| 645 | Nitric Oxide Signalling in Vascular Control and Cardiovascular Risk. 2012 , | 1 |
| 644 | Biomarkers in hemodialysis patients. 2012 , 57, 29-56 | 8 |

| | | | |
|-----|--|-----|-----|
| 643 | The Effects of Antihypertensive Agents in Metabolic Syndrome Benefits Beyond Blood Pressure Control. 2012 , | | 1 |
| 642 | The use of integrated and intelligent testing strategies in the prediction of toxic hazard and in risk assessment. 2012 , 745, 221-53 | | 6 |
| 641 | Future potential biomarkers for postinterventional restenosis and accelerated atherosclerosis. <i>Biomarkers in Medicine</i> , 2012 , 6, 53-66 | 2.3 | 2 |
| 640 | Cardiovascular Nanomedicine: Challenges and Opportunities. 2012 , 249-281 | | 2 |
| 639 | 25-Hydroxyvitamin D levels in the outpatient population of a northern Italy region. 2012 , 5, 63-66 | | |
| 638 | Genetic causation of neointimal hyperplasia in hemodialysis vascular access dysfunction. 2012 , 25, 65-73 | | 9 |
| 637 | Blood biomarkers in stroke: research and clinical practice. 2012 , 7, 435-9 | | 30 |
| 636 | Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review. 2012 , 29, 567-77 | | 49 |
| 635 | Differential associations between blood biomarkers of inflammation, oxidation, and lipid metabolism with varying forms of coronary atherosclerotic plaque as quantified by coronary CT angiography. 2012 , 28, 183-92 | | 22 |
| 634 | A proteomic view of isoproterenol induced cardiac hypertrophy: prohibitin identified as a potential biomarker in rats. 2013 , 11, 130 | | 41 |
| 633 | Lower ratio of high-molecular-weight adiponectin level to total may be associated with coronary high-risk plaque. 2013 , 6, 83 | | 4 |
| 632 | Gesundheitliche Eigenverantwortung im Kontext Individualisierter Medizin. 2013 , 25, 243-250 | | 12 |
| 631 | Association of inflammatory markers with the morphology and extent of coronary plaque as evaluated by 64-slice multidetector computed tomography in patients with stable coronary artery disease. 2013 , 29, 1149-58 | | 14 |
| 630 | Utility of cardiac biomarkers during adulticide treatment of heartworm disease (<i>Dirofilaria immitis</i>) in dogs. 2013 , 197, 244-50 | | 12 |
| 629 | New biomarkers and heart failure. 2013 , 55, e345-e354 | | 4 |
| 628 | Peripheral blood pressure by Dinamap and central blood pressure by applanation tonometry in outpatient general practice. 2013 , 32, 497-503 | | 2 |
| 627 | Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. 2013 , 47, 321-32 | | 158 |
| 626 | Biomarkers in organ failure. 2013 , 3, 97-104 | | |

| | | | |
|-----|--|-----|-----|
| 625 | Clinical correlates of change in inflammatory biomarkers: The Framingham Heart Study. <i>Atherosclerosis</i> , 2013 , 228, 217-23 | 3.1 | 38 |
| 624 | Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis. 2013 , 20, 212-20 | | 43 |
| 623 | Lung cancer biomarkers for the assessment of modified risk tobacco products: an oxidative stress perspective. 2013 , 18, 183-95 | | 34 |
| 622 | Individual risk prediction model for incident cardiovascular disease: a Bayesian clinical reasoning approach. 2013 , 167, 2008-12 | | 7 |
| 621 | Assessment of macrophage migration inhibitory factor in humans: protocol for accurate and reproducible levels. 2013 , 63, 236-42 | | 23 |
| 620 | Clinical utility of biomarkers in chronic kidney disease and chronic heart failure. 2013 , 39, 128-39 | | 1 |
| 619 | Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. 2013 , 139, 32-40 | | 152 |
| 618 | The WAP four-disulfide core domain protein HE4: a novel biomarker for heart failure. 2013 , 1, 164-9 | | 29 |
| 617 | Natriuretic peptides and primary prevention: the new world?. 2013 , 62, 1373-5 | | 6 |
| 616 | Peripheral blood pressure by Dinamap and central blood pressure by applanation tonometry in outpatient general practice. 2013 , 32, 497-503 | | 3 |
| 615 | Increased plasma levels of intermedin and brain natriuretic peptide associated with severity of coronary stenosis in acute coronary syndrome. 2013 , 42, 84-8 | | 19 |
| 614 | AUStralian Indigenous Chronic Disease Optimisation Study (AUSI-CDS) prospective observational cohort study to determine if an established chronic disease health care model can be used to deliver better heart failure care among remote Indigenous Australians: Proof of concept-study <i>Heart Lung and Circulation</i> 2013 , 22, 828-9 | 1.8 | 10 |
| 613 | DNAzyme footprinting: detecting protein-aptamer complexation on surfaces by blocking DNAzyme cleavage activity. 2013 , 135, 2072-5 | | 31 |
| 612 | A decade of plant proteomics and mass spectrometry: translation of technical advancements to food security and safety issues. 2013 , 32, 335-65 | | 59 |
| 611 | Bias in associations of emerging biomarkers with cardiovascular disease. 2013 , 173, 664-71 | | 70 |
| 610 | Biomarkers for incident CKD: a new framework for interpreting the literature. 2013 , 9, 478-83 | | 27 |
| 609 | Diagnosis: Biomarkers of cardiovascular outcomes--bonanza or bias?. 2013 , 9, 381-2 | | 2 |
| 608 | Obesity: Sleeve gastrectomy-the ideal choice for weight-loss surgery. 2013 , 9, 382-4 | | 10 |

| | | |
|-----|---|-----|
| 607 | Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest. 2013 , 168, 1322-7 | 33 |
| 606 | Determinants of plasma copeptin: a systematic investigation in a pediatric mechanical ventilation model. 2013 , 185, 222-7 | 20 |
| 605 | Single lipid vesicle assay for characterizing single-enzyme kinetics of phospholipid hydrolysis in a complex biological fluid. 2013 , 135, 14151-8 | 29 |
| 604 | Relation between leukocyte telomere length and incident coronary heart disease events (from the 1995 Canadian Nova Scotia Health Survey). 2013 , 111, 962-7 | 25 |
| 603 | Effect of lower sodium intake on health: systematic review and meta-analyses. 2013 , 346, f1326 | 715 |
| 602 | Cardiovascular risk in juvenile idiopathic arthritis. 2013 , 52, 1163-71 | 39 |
| 601 | Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction. 2013 , 54, 59-73 | 8 |
| 600 | Integration of biosensors and drug delivery technologies for early detection and chronic management of illness. 2013 , 13, 7680-713 | 38 |
| 599 | [Not Available]. 2013 , 102, 529-33 | |
| 598 | Biomarkers for cardiovascular risk in children. 2013 , 28, 103-14 | 31 |
| 597 | Lung congestion as a risk factor in end-stage renal disease. 2013 , 36, 184-91 | 24 |
| 596 | Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. 2013 , 346, f1378 | 448 |
| 595 | Midregional pro-atrial natriuretic peptide in the general population/Insights from the Gutenberg Health Study. 2013 , 51, 1125-33 | 12 |
| 594 | Ambulatory arterial stiffness index: Is there an additional value to characterize cardiovascular risk in children with kidney transplant?. 2013 , 17, 595-7 | 1 |
| 593 | Blood-based gene expression tests: promises and limitations. 2013 , 6, 139-40 | 10 |
| 592 | Biomarker research and leading causes of death worldwide: a rather feeble relationship. 2013 , 51, 1691-3 | 17 |
| 591 | Proteomics and metabolomics in renal transplantation-quo vadis?. 2013 , 26, 225-41 | 35 |
| 590 | Evaluation of a high-sensitivity assay for measurement of canine and feline serum cardiac troponin I. 2013 , 42, 490-8 | 33 |

| | | |
|-----|---|--------|
| 589 | Biomarkers of endothelial activation/dysfunction in infectious diseases. 2013 , 4, 507-16 | 161 |
| 588 | Cyclophilin A is a promising predictor of coronary artery disease. 2013 , 77, 321-2 | 2 |
| 587 | Endobiogeny: a global approach to systems biology (part 1 of 2). 2013 , 2, 64-78 | 7 |
| 586 | Biomarkers in Drug Discovery and Development. 2013 , 185-194 | |
| 585 | Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. 2013 , 62, 149-63 | 156 |
| 584 | Biomarkers, the molecular gaze and the transformation of cancer survivorship. 2013 , 8, 124-143 | 24 |
| 583 | An internationally generalizable risk index for mortality after one year of antiretroviral therapy. 2013 , 27, 563-72 | 139 |
| 582 | An elevated ratio of placental growth factor to soluble fms-like tyrosine kinase-1 predicts adverse outcomes in patients with stable coronary artery disease. 2013 , 52, 1019-27 | 17 |
| 581 | Examination of serum pregnancy-associated plasma protein A clinical value in acute coronary syndrome prediction and monitoring. 2013 , 9, 14-20 | 4 |
| 580 | Modifying cardiovascular risk factors: new markers of cardiovascular damage. 2013 , 19, 2335-40 | 1 |
| 579 | Editorial (hot topic: cardiovascular disease biomarkers: from tradition to modernity). 2013 , 13, 79-81 | 2 |
| 578 | The role of natriuretic peptides for the diagnosis of left ventricular dysfunction. 2013 , 2013, 784670 | 9 |
| 577 | Emerging families of biomarkers for coronary artery disease: inflammatory mediators. 2013 , 9, 435-56 | 33 |
| 576 | Metabolic biomarkers for predicting cardiovascular disease. 2013 , 9, 37-45 | 22 |
| 575 | Heart Failure. 2013 , 540-556 | |
| 574 | Evolution of biomarker guided therapy for heart failure: current concepts and trial evidence. <i>Current Cardiology Reviews</i> , 2015 , 11, 80-9 | 2.4 11 |
| 573 | Single step PCR for the identification of Low Density Lipoprotein Receptor (LDL-R) gene mutations. 2014 , 30, 830-3 | 3 |
| 572 | Molecular imaging of the atherosclerotic plaque using positron emission tomography. 2014 , 44, 139-45 | |

- 571 The relevance of coagulation in cardiovascular disease: what do the biomarkers tell us?. **2014**, 112, 860-7 38
- 570 A novel use of biomarkers in the modeling of cancer activity based on the theory of endobiogeny. **2014**, 3, 55-60 3
- 569 Incorporating biomarkers into clinical trials in cardiovascular medicine. **2014**, 121
- 568 Increased myeloperoxidase plasma levels in patients with Alzheimer's disease. **2014**, 39, 557-64 43
- 567 *Caenorhabditis elegans* as a model for biomarkers of diseases and toxicities. **2014**, 113-128 3
- 566 Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury. **2014**, 126, 377-400 27
- 565 Academic College of Emergency Experts in India's INDO-US Joint Working Group and OPUS12 Foundation Consensus Statement on Creating A Coordinated, Multi-Disciplinary, Patient-Centered, Global Point-of-Care Biomarker Discovery Network. **2014**, 4, 200-8 10
- 564 Longitudinal monitoring of the serotonin transporter gene expression to assess major depressive episode evolution. **2014**, 70, 220-7 6
- 563 The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure. **2014**, 14, 257-66 28
- 562 Application of chemometric techniques in search of clinically applicable biomarkers of disease. **2014**, 75, 283-90 9
- 561 Signature of subclinical femoral artery atherosclerosis in peripheral blood mononuclear cells. **2014**, 44, 539-48 5
- 560 The relationship between inflammatory and oxidative stress biomarkers, atherosclerosis and rheumatic diseases. **2014**, 20, 585-600 22
- 559 Retinol-binding protein 4 levels and susceptibility to ischaemic events in men. **2014**, 44, 266-75 22
- 558 Modifying matrix remodeling to prevent heart failure. **2014**, 41-60 1
- 557 Six-month follow-up study of health markers of nanomaterials among workers handling engineered nanomaterials. **2014**, 8 Suppl 1, 100-10 71
- 556 Transient and persistent metabolomic changes in plasma following chronic cigarette smoke exposure in a mouse model. **2014**, 9, e101855 30
- 555 Association of markers of hemostasis with death in HIV-infected women. **2014**, 67, 287-94 4
- 554 Central pulse pressure links microalbuminuria with plasma B-type natriuretic peptide elevation: causal implication for cardiorenal syndrome in hypertension. **2014**, 32, 1665-71; discussion 1671 8

| | | |
|-----|---|--------|
| 553 | Hormone therapy and hemostasis among postmenopausal women: a review. 2014 , 21, 753-62 | 37 |
| 552 | Lipocalin-type prostaglandin D synthase is not a biomarker of atherosclerotic manifestations. 2014 , 74, 219-27 | 1 |
| 551 | Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention. 2014 , 129, 178-88 | 17 |
| 550 | Mechanistic insights into the link between inflammation and cardiovascular disease: rheumatoid arthritis as a human model of inflammation. 2014 , 7, 575-7 | 4 |
| 549 | The Evaluation of Novel Biomarkers and the Multiple Biomarker Approach in the Prediction of Cardiovascular Disease. 2014 , 8, 1 | 3 |
| 548 | Predictive value of high-sensitivity troponin-I for future adverse cardiovascular outcome in stable patients with type 2 diabetes mellitus. 2014 , 13, 63 | 24 |
| 547 | Multimarker approach with cystatin C, N-terminal pro-brain natriuretic peptide, C-reactive protein and red blood cell distribution width in risk stratification of patients with acute coronary syndromes. 2014 , 33, 127-136 | 3 |
| 546 | Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA ₂) and lipoprotein(a) (Lp(a)). 2014 , 28, 281-94 | 19 |
| 545 | Elevated plasma free fatty acids are associated with sudden death: a prospective community-based evaluation at the time of cardiac arrest. 2014 , 11, 691-6 | 13 |
| 544 | Plasma proteome profiling of atherosclerotic disease manifestations reveals elevated levels of the cytoskeletal protein vinculin. 2014 , 101, 141-53 | 29 |
| 543 | Microfluidic platforms for biomarker analysis. 2014 , 14, 1496-514 | 96 |
| 542 | Surface plasmon resonance applications in clinical analysis. 2014 , 406, 2303-23 | 121 |
| 541 | Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. 2014 , 31, 297-307 | 39 |
| 540 | Microfluidic blood cell sorting: now and beyond. 2014 , 10, 1687-703 | 107 |
| 539 | Emerging technologies for hybridization based single nucleotide polymorphism detection. 2014 , 139, 353-70 | 57 |
| 538 | Molecular imaging of atherosclerosis: clinical state-of-the-art. 2014 , 100, 1469-77 | 26 |
| 537 | Conventional therapies fail to target inflammation and immune imbalance in subjects with stable coronary artery disease: a system-based approach. <i>Atherosclerosis</i> , 2014 , 237, 623-31 | 3.1 12 |
| 536 | Hollow-Core Coaxial Fiber Sensor for Biophotonic Detection. 2014 , 20, 134-142 | 6 |

| | | |
|-----|---|--------|
| 535 | Predicting carotid artery disease and plaque instability from cell-derived microparticles. 2014 , 48, 489-95 | 26 |
| 534 | NMR-based lipidomic analysis of blood lipoproteins differentiates the progression of coronary heart disease. 2014 , 13, 2585-98 | 25 |
| 533 | Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects. <i>Atherosclerosis</i> , 2014 , 237, 60-6 | 3.1 33 |
| 532 | Análisis proteómico del líquido cefalorraquídeo de pacientes con lupus neuropsiquiátrico, un abordaje inicial para la búsqueda de biomarcadores. 2014 , 21, 115-124 | 3 |
| 531 | Vulnerable plaque imaging and acute coronary syndrome. 2014 , 56, e362-e368 | 6 |
| 530 | The potential value of integrated natriuretic peptide and echo-guided heart failure management. 2014 , 12, 27 | 11 |
| 529 | Lipidomics reveals a link between CYP1B1 and SCD1 in promoting obesity. 2014 , 13, 2679-87 | 33 |
| 528 | Biomarkers for neurology: Guides and lines. 2014 , 83, 1130-1 | 6 |
| 527 | Recent developments in proteomic methods and disease biomarkers. 2014 , 139, 3836-51 | 15 |
| 526 | Serum adropin levels are decreased in patients with acute myocardial infarction. 2014 , 190-191, 46-9 | 56 |
| 525 | C-reactive protein and brain natriuretic peptide as predictors of adverse events after lower extremity endovascular revascularization. 2014 , 60, 652-60 | 31 |
| 524 | Ezrin expression and cell survival regulation in colorectal cancer. 2014 , 26, 868-79 | 27 |
| 523 | Discussion. 2014 , 60, 659-60 | |
| 522 | Multimarker approach with cystatin C, N-terminal pro-brain natriuretic peptide, C-reactive protein and red blood cell distribution width in risk stratification of patients with acute coronary syndromes. 2014 , 33, 127-36 | 6 |
| 521 | Charting a roadmap for heart failure biomarker studies. 2014 , 2, 477-88 | 54 |
| 520 | Recent development of sandwich assay based on the nanobiotechnologies for proteins, nucleic acids, small molecules, and ions. 2014 , 114, 7631-77 | 194 |
| 519 | Hard, harder, hardest: principal stratification, statistical identifiability, and the inherent difficulty of finding surrogate endpoints. 2014 , 11, 14 | 2 |
| 518 | Secoiridoids delivered as olive leaf extract induce acute improvements in human vascular function and reduction of an inflammatory cytokine: a randomised, double-blind, placebo-controlled, cross-over trial. 2015 , 114, 75-83 | 54 |

| | | |
|-----|--|--------|
| 517 | Distribution and biomarker of carbon-14 labeled fullerene C60 ($^{14}\text{C}(\text{U})\text{C}_{60}$) in pregnant and lactating rats and their offspring after maternal intravenous exposure. 2015 , 35, 1438-51 | 26 |
| 516 | Utility of mass spectrometry for the diagnosis of the unstable coronary plaque. 2015 , 2015, 25 | 4 |
| 515 | Recoordination of opposing walls drives the response to cardiac resynchronization therapy: a longitudinal study using a strain discoordination index. 2015 , 16, 736-42 | 3 |
| 514 | Susceptibility to quantum dot induced lung inflammation differs widely among the Collaborative Cross founder mouse strains. 2015 , 289, 240-50 | 28 |
| 513 | Perspectives on next steps in classification of oro-facial pain - Part 3: biomarkers of chronic oro-facial pain - from research to clinic. 2015 , 42, 956-66 | 14 |
| 512 | Discriminating different causes of transfusion-associated pulmonary edema. 2015 , 55, 1825-8 | 2 |
| 511 | Novel biomarkers for risk stratification in pulmonary arterial hypertension. 2015 , 1, | 14 |
| 510 | The additive value of multiple biomarkers in prediction of premature coronary artery disease. 2015 , 70, 205-10 | 4 |
| 509 | Urinary proteomic biomarkers to predict cardiovascular events. 2015 , 9, 610-7 | 26 |
| 508 | Severe multivessel coronary artery disease and high-sensitive troponin T. 2015 , 12, 139-44 | 1 |
| 507 | Association between inflammatory biomarkers and thin-cap fibroatheroma detected by optical coherence tomography in patients with coronary heart disease. 2015 , 11, 505-12 | 15 |
| 506 | Biomarkers, erectile dysfunction, and cardiovascular risk prediction: the latest of an evolving concept. 2015 , 17, 17-20 | 11 |
| 505 | Bridging the Gap between Translational and Outcome Research in Cardiovascular Disease. 2015 , 2015, 454680 | 4 |
| 504 | 3-nitrotyrosine modified proteins in atherosclerosis. <i>Disease Markers</i> , 2015 , 2015, 708282 | 3.2 36 |
| 503 | Biomarkers of lung injury in cardiothoracic surgery. <i>Disease Markers</i> , 2015 , 2015, 472360 | 3.2 7 |
| 502 | Elevation of the Serum Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 in Coronary Artery Disease. 2015 , 45, 364-71 | 21 |
| 501 | Utility of Biomarkers in Contemporary Management of Chronic Heart Failure. 2015 , 3, | |
| 500 | Genetic testing in hyperlipidemia. 2015 , 33, 267-75 | 4 |

| | | |
|-----|---|-----|
| 499 | Association of microalbuminuria with ischemic heart disease in non-diabetic Asian-Indians: A case control study. 2015 , 5, 6-10 | 3 |
| 498 | Clinical Use of Serum Biomarkers in the Prediction of Cardiovascular Risk. 2015 , 21-38 | |
| 497 | Biomarkers of Cardiometabolic Risk, Inflammation and Disease. 2015 , | 2 |
| 496 | High sensitivity automated multiplexed immunoassays using photonic crystal enhanced fluorescence microfluidic system. 2015 , 73, 32-40 | 34 |
| 495 | Clinical interpretation of high sensitivity troponin T. 2015 , 145, 258-263 | |
| 494 | Population-Based Studies. 2015 , 21-31 | |
| 493 | Inflammatory Biomarkers in Post-infarction Heart Failure and Cardiac Remodeling. 2015 , 105-116 | |
| 492 | Central pressure should be used in clinical practice. 2015 , 9, 1 | 11 |
| 491 | [Clinical interpretation of high sensitivity troponin T]. 2015 , 145, 258-63 | 3 |
| 490 | Capillary zone electrophoresis on-line coupled to mass spectrometry: A perspective application for clinical proteomics. 2015 , 9, 453-68 | 41 |
| 489 | Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. 2015 , 52, 70-85 | 185 |
| 488 | Atherosclerosis-Related Circulating MicroRNAs as a Predictor of Stroke Recurrence. 2015 , 6, 191-7 | 51 |
| 487 | A novel approach to identify optimal metabolotypes of elongase and desaturase activities in prevention of acute coronary syndrome. 2015 , 11, 1327-1337 | 2 |
| 486 | Aptamers Selected by Cell-SELEX for Theranostics. 2015 , | 4 |
| 485 | Research on potential biomarkers in hereditary hemorrhagic telangiectasia. 2015 , 6, 115 | 25 |
| 484 | Risk stratification in non-ST elevation acute coronary syndromes: Risk scores, biomarkers and clinical judgment. 2015 , 8, 131-137 | 15 |
| 483 | Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. 2015 , 65, 2449-56 | 132 |
| 482 | Effects of Exercise Training on Cardiorespiratory Fitness and Biomarkers of Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2015 , 4, | 322 |

| | | |
|-----|---|-----|
| 481 | Cardiac Fibrosis and Heart Failure: Cause or Effect?. 2015, | 3 |
| 480 | Current applications of biomarkers in cardiomyopathies. 2015, 13, 825-37 | 9 |
| 479 | Functionalized polythiophenes: Recognition materials for chemosensors and biosensors of superior sensitivity, selectivity, and detectability. 2015, 47, 1-25 | 102 |
| 478 | Enzyme-mediated single-nucleotide variation detection at room temperature with high discrimination factor. 2015, 6, 1206-1211 | 47 |
| 477 | Identification of Predictable Biomarkers in Conjunction to Framingham Risk Score to Predict the Risk for Cardiovascular disease (CVD) in Non Cardiac Subjects. 2015, 9, BC23-7 | 3 |
| 476 | Giant magnetoresistive-based biosensing probe station system for multiplex protein assays. 2015, 70, 61-8 | 57 |
| 475 | Molecular markers of arterial hypertension in patients with normotony, pre-hypertension and hypertension. 2015, 158, 604-6 | 2 |
| 474 | Anti-inflammatory and antioxidant activities of the nonlipid (aqueous) components of sesame oil: potential use in atherosclerosis. 2015, 18, 393-402 | 22 |
| 473 | The mechanism by which moderate alcohol consumption influences coronary heart disease. 2015, 14, 33 | 26 |
| 472 | How do high glycemic load diets influence coronary heart disease?. 2015, 12, 6 | 12 |
| 471 | Correlates of Incident Cognitive Impairment in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. 2015, 29, 466-86 | 12 |
| 470 | Analytical validation of novel cardiac biomarkers used in clinical trials. 2015, 169, 674-83 | 11 |
| 469 | Markers of atherosclerosis in relation to presence and progression of knee osteoarthritis: a population-based cohort study. 2015, 54, 1692-8 | 24 |
| 468 | Basics of Clinical Trials. 2015, 383-413 | |
| 467 | Review on cardiovascular risk prediction. 2015, 33, 62-70 | 25 |
| 466 | Predictivity Classification of Biomarkers and Scores. 2015, 151-154 | |
| 465 | Development of Biomarkers. 2015, 145-149 | 1 |
| 464 | Supplementation of a standardized extract from <i>Phyllanthus emblica</i> improves cardiovascular risk factors and platelet aggregation in overweight/class-1 obese adults. 2015, 18, 415-20 | 27 |

| | | |
|-----|--|--------|
| 463 | The promise of biological markers for treatment response in first-episode psychosis: a systematic review. 2015 , 41, 559-73 | 65 |
| 462 | Matrix Metalloproteinase 9 (MMP-9). 2015 , 237-259 | 1 |
| 461 | The mechanisms by which antidepressants may reduce coronary heart disease risk. 2015 , 15, 82 | 8 |
| 460 | Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction. 2015 , 9, 55-62 | 4 |
| 459 | Systemic circulatory influences on retinal microvascular function in middle-age individuals with low to moderate cardiovascular risk. 2015 , 93, e266-74 | 7 |
| 458 | Homocysteinemia After Hypertensive Pregnancy Disorders at Term. 2015 , 24, 524-9 | 3 |
| 457 | Endothelial Function in the Stress Echocardiography Laboratory. 2015 , 431-448 | |
| 456 | Sensing the Whole Body and Clinical Diagnostics. 2015 , 677-717 | |
| 455 | Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis. 2015 , 136, 1120-5 | 13 |
| 454 | Sensitive Detection of Cardiac Biomarkers Using a Magnetic Microbead Immunoassay. 2015 , 7, 8632-8639 | 8 |
| 453 | Decreased miR-187 induces retinal ganglion cell apoptosis through upregulating SMAD7 in glaucoma. 2015 , 75, 19-25 | 22 |
| 452 | Oxidative stress, inflammation, and markers of cardiovascular health. <i>Atherosclerosis</i> , 2015 , 243, 38-43 | 3.1 31 |
| 451 | Arterial Stiffness. 2015 , | 9 |
| 450 | Role of dietary pro-oxidants in the maintenance of health and resilience to oxidative stress. 2015 , 59, 1229-48 | 29 |
| 449 | Risk Classification with an Adaptive Naive Bayes Kernel Machine Model. 2015 , 110, 393-404 | 16 |
| 448 | Cardiac biomarker testing in the clinical laboratory: where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. 2015 , 443, 17-24 | 63 |
| 447 | Cardiovascular OCT Imaging. 2015 , | 4 |
| 446 | Protective role of probiotic lactic acid bacteria against dietary fumonisin B1-induced toxicity and DNA-fragmentation in sprague-dawley rats. 2015 , 45, 530-50 | 16 |

| | | |
|-----|--|----|
| 445 | A sensitive phage-based capture ELISA for sub-femtomolar detection of protein variants directly from biological samples. 2015 , 31, 289-98 | 11 |
| 444 | Usefulness of Faecal Markers in Cow Milk Protein Immunomediated Reactions. 2016 , | 1 |
| 443 | Usefulness of Cardiac Biomarkers in the Evaluation of Prognosis and Cardiac Involvement in Patients with Acute Aortic Syndrome. 2016 , 5, 27 | |
| 442 | Accurate Quantification of Disease Markers in Human Serum Using Iron Oxide Nanoparticle-linked Immunosorbent Assay. 2016 , 6, 1353-61 | 14 |
| 441 | Novel Biomarkers to Understand Cardiovascular Complications in Diabetes. 2016 , | 1 |
| 440 | Relationship of Inflammatory Biomarkers with Severity of Peripheral Arterial Disease. 2016 , 2016, 6015701 | 10 |
| 439 | Brachial-Ankle PWV: Current Status and Future Directions as a Useful Marker in the Management of Cardiovascular Disease and/or Cardiovascular Risk Factors. 2016 , 23, 128-46 | 51 |
| 438 | Serum Albumin Is an Independent Predictor of Clinical Outcomes in Critically Ill Children. 2016 , 17, e50-7 | 45 |
| 437 | Screen-printed Electrochemical Immunosensors for the Detection of Cancer and Cardiovascular Biomarkers. 2016 , 28, 1700-1715 | 56 |
| 436 | HDLs in crises. 2016 , 27, 264-73 | 19 |
| 435 | Plasma B-type natriuretic peptide concentration is independently associated with kidney function decline in Japanese patients with chronic kidney disease. 2016 , 34, 753-61 | 9 |
| 434 | Serum Salusin- β Levels Are Correlated with Slow Coronary Flow. 2016 , 20, 393-7 | 1 |
| 433 | Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials. 2016 , 3, 1-28 | 92 |
| 432 | High-intensity interval training versus moderate-intensity steady-state training in UK cardiac rehabilitation programmes (HIIT or MISS UK): study protocol for a multicentre randomised controlled trial and economic evaluation. 2016 , 6, e012843 | 11 |
| 431 | Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction. 2017 , 243, 79-108 | 4 |
| 430 | Troponin in Cardiovascular Disease Prevention: Updates and Future Direction. 2016 , 18, 12 | 20 |
| 429 | The Monocyte-to-Lymphocyte Ratio Correlates with Psycho-Neuro-Inflammatory Factors in Patients with Stable Coronary Artery Disease. 2016 , 23, 67-74 | 17 |
| 428 | A two-layer assay for single-nucleotide variants utilizing strand displacement and selective digestion. 2016 , 82, 248-54 | 25 |

| | | | |
|-----|--|------|-----|
| 427 | Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases. 2016 , 53, 396-408 | | 28 |
| 426 | Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy. 2016 , 173, 30-57 | | 49 |
| 425 | Blood-Based Biomarkers for Metabolic Syndrome. 2016 , 27, 363-374 | | 52 |
| 424 | The search for efficient diagnostic and prognostic biomarkers of heart failure. 2016 , 12, 327-37 | | 1 |
| 423 | "State-of-Art" paper of the Italian Working Group on Atherosclerosis: Preclinical assessment of early coronary atherosclerosis. 2016 , 214, 442-7 | | 10 |
| 422 | Biomarkers in heart failure: the importance of inconvenient details. 2016 , 3, 3-10 | | 14 |
| 421 | Ageing effect on flicker-induced diameter changes in retinal microvessels of healthy individuals. 2016 , 94, e35-42 | | 23 |
| 420 | Quantitative Metabolomic Profiling of Plasma, Urine, and Liver Extracts by H NMR Spectroscopy Characterizes Different Stages of Atherosclerosis in Hamsters. 2016 , 15, 3500-3510 | | 20 |
| 419 | Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension. <i>Biomarkers in Medicine</i> , 2016 , 10, 841-51 | 2.3 | 1 |
| 418 | Genetic markers: Potential candidates for cardiovascular disease. 2016 , 220, 914-23 | | 4 |
| 417 | Photoacoustic tomography: applications for atherosclerosis imaging. 2016 , 18, 084005 | | 7 |
| 416 | Variation in serum biomarkers with sex and female hormonal status: implications for clinical tests. <i>Scientific Reports</i> , 2016 , 6, 26947 | 4.9 | 22 |
| 415 | Carotid Intima-Media Thickness as a Cardiovascular Risk Factor and Imaging Pathway of Atherosclerosis. 2016 , 15, 152-160 | | 13 |
| 414 | Oral health and coronary heart disease. 2016 , 16, 122 | | 17 |
| 413 | Predictive Neuroimaging Markers of Psychotherapy Response: A Systematic Review. 2016 , 24, 396-405 | | 28 |
| 412 | Worldwide Exposures to Cardiovascular Risk Factors and Associated Health Effects: Current Knowledge and Data Gaps. <i>Circulation</i> , 2016 , 133, 2314-33 | 16.7 | 119 |
| 411 | Reevaluation of cardiac risk scores and multiple biomarkers for the prediction of first major cardiovascular events and death in the drug-eluting stent era. 2016 , 219, 180-5 | | 9 |
| 410 | A Review of Cutoffs for Nutritional Biomarkers. 2016 , 7, 112-20 | | 38 |

| | | | |
|-----|---|-----|----|
| 409 | Myocardial Fibrosis in Hypertensive Heart Failure: Does Quality Rather Than Quantity Matter?. 2016 , 67, 261-3 | | 3 |
| 408 | Systems Medicine. 2016 , | | 5 |
| 407 | Development and evaluation of multi-marker risk scores for clinical prognosis. 2016 , 25, 255-71 | | 15 |
| 406 | Physical models for the normal YORP and diurnal Yarkovsky effects. 2016 , 458, 3977-3989 | | 12 |
| 405 | Genetic Testing in Hyperlipidemia. 2016 , 45, 129-40 | | 3 |
| 404 | Cardiac ScoreCard: A Diagnostic Multivariate Index Assay System for Predicting a Spectrum of Cardiovascular Disease. 2016 , 54, 136-147 | | 22 |
| 403 | Proteomic Profile of Unstable Atheroma Plaque: Increased Neutrophil Defensin 1, Clusterin, and Apolipoprotein E Levels in Carotid Secretome. 2016 , 15, 933-44 | | 19 |
| 402 | Nonclassical human leukocyte antigen (HLA-G, HLA-E, and HLA-F) in coronary artery disease. 2016 , 77, 325-9 | | 7 |
| 401 | Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease. <i>Biomarkers in Medicine</i> , 2016 , 10, 95-106 | 2-3 | 4 |
| 400 | Network-Assisted Disease Classification and Biomarker Discovery. 2016 , 1386, 353-74 | | 8 |
| 399 | Novel interactions of domain III from the envelope glycoprotein of dengue 2 virus with human plasma proteins. 2016 , 131, 205-213 | | 11 |
| 398 | What does serum γ -glutamyltransferase tell us as a cardiometabolic risk marker?. 2016 , 53, 312-32 | | 26 |
| 397 | Novel biomarkers with potential for cardiovascular risk reclassification. 2017 , 22, 189-199 | | 10 |
| 396 | Realising the Potential of Urine and Saliva as Diagnostic Tools in Sport and Exercise Medicine. 2017 , 47, 11-31 | | 39 |
| 395 | Arterial (Aortic) Stiffness in Patients with Resistant Hypertension: from Assessment to Treatment. 2017 , 19, 2 | | 20 |
| 394 | Global Risk Assessment to Guide Blood Pressure Management in Cardiovascular Disease Prevention. 2017 , 69, e2-e9 | | 23 |
| 393 | Miniaturized electrophoresis electrochemical protein sensor (MEEPS) for multiplexed protein detections. 2017 , 244, 823-830 | | 5 |
| 392 | Single-Molecule Counting of Point Mutations by Transient DNA Binding. <i>Scientific Reports</i> , 2017 , 7, 43824.9 | | 19 |

| | | |
|-----|---|----|
| 391 | Monocyte Chemoattractant Protein-1 and Large Artery Structure and Function in Young Individuals: The African-PREDICT Study. 2017 , 19, 67-74 | 8 |
| 390 | Factor XII as a Risk Marker for Hemorrhagic Stroke: A Prospective Cohort Study. 2017 , 7, 84-94 | 6 |
| 389 | Association of low serum albumin concentration and adverse cardiovascular events in stable coronary heart disease. 2017 , 241, 1-5 | 43 |
| 388 | Extracellular Vesicles in Metabolic Syndrome. 2017 , 120, 1674-1686 | 81 |
| 387 | Anthracycline induced cardiotoxicity: biomarkers and "Omics" technology in the era of patient specific care. 2017 , 6, 17 | 19 |
| 386 | Comparative study of cardio-protective effects of zinc oxide nanoparticles and zinc sulfate in streptozotocin-induced diabetic rats. 2017 , 42, 129-141 | 16 |
| 385 | Systems Metabolomics for Prediction of Metabolic Syndrome. 2017 , 16, 2262-2272 | 28 |
| 384 | Heart Failure. 2017 , | 4 |
| 383 | Schizophrenia: A review of potential biomarkers. 2017 , 93, 37-49 | 30 |
| 382 | Diagnosis of cardiac surgery-associated acute kidney injury: differential roles of creatinine, chitinase 3-like protein 1 and neutrophil gelatinase-associated lipocalin: a prospective cohort study. 2017 , 7, 24 | 25 |
| 381 | A novel role for miR-133a in centrally mediated activation of the renin-angiotensin system in congestive heart failure. 2017 , 312, H968-H979 | 10 |
| 380 | Activation of CD137 Signaling Promotes Angiogenesis in Atherosclerosis via Modulating Endothelial Smad1/5-NFATc1 Pathway. 2017 , 6, | 19 |
| 379 | Post-translational regulation of neuronal nitric oxide synthase: implications for sympathoexcitatory states. 2017 , 21, 11-22 | 22 |
| 378 | State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease. 2017 , 63, 165-176 | 26 |
| 377 | Natural Products against Drug-Induced Cardiotoxicity. 2017 , 121-147 | 2 |
| 376 | A Biomarker Ocular: Circulating MicroRNAs Toward Diagnostics for Acute Ischemic Stroke. 2017 , 121, 905-907 | 9 |
| 375 | Myeloid-related protein-8/14 in acute coronary syndrome. 2017 , 249, 25-31 | 12 |
| 374 | Physical Inactivity and the Economic and Health Burdens Due to Cardiovascular Disease: Exercise as Medicine. 2017 , 999, 3-18 | 10 |

| | | | |
|-----|--|-----|----|
| 373 | The role of biomarkers in dilated cardiomyopathy: Assessment of clinical severity and reverse remodeling. 2017 , 36, 709-716 | | 9 |
| 372 | Oxidative stress in ischemia and reperfusion: current concepts, novel ideas and future perspectives. <i>Biomarkers in Medicine</i> , 2017 , 11, 11031-1040 | 2.3 | 50 |
| 371 | High-Throughput Separation of White Blood Cells From Whole Blood Using Inertial Microfluidics. 2017 , 11, 1422-1430 | | 27 |
| 370 | Pentraxin 3 and atherosclerosis among type 2 diabetic patients. 2017 , 12, 92-98 | | |
| 369 | Targeted Protein Biomarker Quantitation by LC-MS. 2017 , 227-244 | | |
| 368 | Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances. 2017 , 13, 548-560 | | 80 |
| 367 | Merging Clinical and Imaging Biomarkers to Tackle Parkinson's Disease. 2017 , 4, 652-662 | | 3 |
| 366 | The Health Benefits of Walking. 2017 , 61-79 | | 16 |
| 365 | A review on ZnO-based electrical biosensors for cardiac biomarker detection. 2017 , 3, FSO196 | | 36 |
| 364 | Age-related diagnostic value of D-dimer testing and the role of inflammation in patients with suspected deep vein thrombosis. <i>Scientific Reports</i> , 2017 , 7, 4591 | 4.9 | 18 |
| 363 | Novel biomarkers of acute kidney injury and chronic kidney disease. 2017 , 24, 84-91 | | 4 |
| 362 | Ultrasensitive cardiac troponin I antibody based nanohybrid sensor for rapid detection of human heart attack. 2017 , 95, 505-510 | | 46 |
| 361 | Novel Biomarkers of Heart Failure. 2017 , 79, 93-152 | | 60 |
| 360 | Cardiovascular disease in patients with rheumatoid arthritis. 2017 , 27, 136-140 | | 48 |
| 359 | Personalized medicine in psychiatry. 2017 , 71, 12-19 | | 37 |
| 358 | Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. 2017 , 27, 123-133 | | 76 |
| 357 | Current Understanding of Atherogenesis. 2017 , 130, 268-282 | | 52 |
| 356 | Predicting Risk of Cognitive Decline in Very Old Adults Using Three Models: The Framingham Stroke Risk Profile; the Cardiovascular Risk Factors, Aging, and Dementia Model; and Oxi-Inflammatory Biomarkers. 2017 , 65, 381-389 | | 25 |

| | | |
|-----|---|-----|
| 355 | The role of biomarkers in dilated cardiomyopathy: Assessment of clinical severity and reverse remodeling. 2017 , 36, 709-716 | 5 |
| 354 | Cardiopulmonary and inflammatory biomarkers in heartworm disease. 2017 , 10, 534 | 9 |
| 353 | The integrated effect of moderate exercise on coronary heart disease. 2017 , 28, 125-133 | 4 |
| 352 | Is Carotid Artery Ultrasound Still Useful Method for Evaluation of Atherosclerosis?. 2017 , 47, 1-8 | 14 |
| 351 | Applying Translational Bioinformatics for Biomarker Discovery. 2017 , 55-65 | |
| 350 | Personalised Interventions-A Precision Approach for the Next Generation of Dietary Intervention Studies. 2017 , 9, | 33 |
| 349 | Can Brain Natriuretic Peptides and Osteoprotegerin Serve As Biochemical Markers for the Detection of Aortic Pathology in Children and Adolescents with Turner Syndrome?. 2017 , 8, 142 | 2 |
| 348 | Design of a New Ultracompact Resonant Plasmonic Multi-Analyte Label-Free Biosensing Platform. 2017 , 17, | 11 |
| 347 | The Ambivalence of Early Diagnosis - Returning Results in Current Alzheimer Research. 2018 , 15, 28-37 | 5 |
| 346 | Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. 2017 , 8, 61837-61845 | 10 |
| 345 | Danger-recognizing proteins, ß-defensin-128 and histatin-3, as potential biomarkers of recurrent coronary events. 2017 , 40, 531-538 | 4 |
| 344 | Biologic Markers in Clinical Trials and Clinical Care. 2017 , 509-519 | |
| 343 | Role of circulating factors in cardiac aging. 2017 , 9, S17-S29 | 11 |
| 342 | Management of chronic heart failure: biomarkers, monitors, and disease management programs. 2014 , 80, 46-54 | 10 |
| 341 | Redefining biomarkers in heart failure. 2018 , 23, 237-253 | 17 |
| 340 | Platinum aptasensor wire arrays for cardiac biomarker detection. 2018 , 15, 55-60 | 6 |
| 339 | Blood biomarkers in ischemic stroke: potential role and challenges in clinical practice and research. 2018 , 55, 294-328 | 53 |
| 338 | Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. 2018 , 50, 693-698 | 970 |

| | | | |
|-----|--|-----|----|
| 337 | Non-coding RNAs as biomarkers for acute myocardial infarction. 2018 , 39, 1110-1119 | | 52 |
| 336 | Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis. 2018 , 11, e004171 | | 11 |
| 335 | A comprehensive review on nano-molybdenum disulfide/DNA interfaces as emerging biosensing platforms. 2018 , 107, 244-258 | | 23 |
| 334 | Carbohydrate antigen 125: a promising tool for risk stratification in heart diseases. <i>Biomarkers in Medicine</i> , 2018 , 12, 367-381 | 2.3 | 15 |
| 333 | Effect of Angiotensin II on Matrix Metalloproteinase-2 Secretion in Human Umbilical Vein Endothelial Cells. 2018 , 71, 233-239 | | 2 |
| 332 | Cardiovascular biomarkers in clinical studies of type 2 diabetes. 2018 , 20, 1350-1360 | | 13 |
| 331 | Recent advances in mass spectrometry-based approaches for proteomics and biologics: Great contribution for developing therapeutic antibodies. 2018 , 185, 147-154 | | 39 |
| 330 | Utility of troponin assays for exclusion of acute cellular rejection after heart transplantation: A systematic review. 2018 , 37, 631-638 | | 12 |
| 329 | Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). 2018 , 168, 631-638 | | 35 |
| 328 | Fluorescence Sandwich Assays for Protein Detection. 2018 , 29-45 | | 1 |
| 327 | Biosensors Based on Sandwich Assays. 2018 , | | 4 |
| 326 | Cell-free DNA as a biomarker in stroke: Current status, problems and perspectives. 2018 , 55, 55-70 | | 14 |
| 325 | Advances in the design of nanomaterial-based electrochemical affinity and enzymatic biosensors for metabolic biomarkers: A review. <i>Mikrochimica Acta</i> , 2018 , 185, 276 | 5.8 | 52 |
| 324 | Implicit Identification with Illness in Patients with Irritable Bowel Syndrome (IBS). 2018 , 42, 328-339 | | 0 |
| 323 | ST2: Current status. 2018 , 70 Suppl 1, S96-S101 | | 29 |
| 322 | Proteomic Biomarkers of Heart Failure. 2018 , 14, 93-107 | | 16 |
| 321 | Myocardial Injury Is Distinguished from Stable Angina by a Set of Candidate Plasma Biomarkers Identified Using iTRAQ/MRM-Based Approach. 2018 , 17, 499-515 | | 11 |
| 320 | Association Between Anti-Citrullinated Fibrinogen Antibodies and Coronary Artery Disease in Rheumatoid Arthritis. 2018 , 70, 1113-1117 | | 6 |

- 319 Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. **2018**, 476, 130-138 58
- 318 Myocardial injury after endovascular revascularization in critical limb ischemia predicts 1-year mortality: a prospective observational cohort study. **2018**, 107, 319-328 8
- 317 A systematic review of the associations between HIV/HCV coinfection and biomarkers of cardiovascular disease. **2018**, 28, e1953 5
- 316 Novel peptidylated surfaces for interference-free electrochemical detection of cardiac troponin I. **2018**, 99, 486-492 39
- 315 Gene detection: An essential process to precision medicine. **2018**, 99, 625-636 13
- 314 Cardiovascular biomarkers modified by exercise. **2018**, 3, 17-17 1
- 313 Neutrophil-Lymphocyte Ratio in Cardiovascular Disease Risk Assessment. **2018**, 2 2
- 312 Unbiased Proteomic Approach Identifies Unique and Coincidental Plasma Biomarkers in Repetitive mTBI and AD Pathogenesis. **2018**, 10, 405 7
- 311 Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. **2018**, 15, 35 5
- 310 OBSOLETE: Biomarkers: Population Screening and Risk-Stratification. **2018**, 22 22
- 309 OBSOLETE: Transcriptome and Epigenome Applications for Coronary Heart Disease Research. **2018**, 16.7 16.7
- 308 Point-of-Care Compatibility of Ultra-Sensitive Detection Techniques for the Cardiac Biomarker Troponin I-Challenges and Potential Value. **2018**, 8, 22 22
- 307 A novel network-based approach for discovering dynamic metabolic biomarkers in cardiovascular disease. **2018**, 13, e0208953 5
- 306 Interaction of graphene electrolyte gate field-effect transistor for detection of cortisol biomarker. **2018**, 7 7
- 305 Untargeted Metabolomics in the Discovery of Novel Biomarkers and Therapeutic Targets for Atherosclerotic Cardiovascular Diseases. **2018**, 18, 166-175 15
- 304 Probing the Virtual Proteome to Identify Novel Disease Biomarkers. *Circulation*, **2018**, 138, 2469-2481 16.7 23
- 303 Biomarker Glycoprotein Acetyls Is Associated With the Risk of a Wide Spectrum of Incident Diseases and Stratifies Mortality Risk in Angiography Patients. **2018**, 11, e002234 19
- 302 An integrated microfluidic platform to perform uninterrupted SELEX cycles to screen affinity reagents specific to cardiovascular biomarkers. **2018**, 122, 104-112 35

| | | | |
|-----|---|-----|-----|
| 301 | Retinal vascular function in asymptomatic individuals with a positive family history of cardiovascular disease. 2018 , 96, e956-e962 | | 5 |
| 300 | Vitamin D in Cardiovascular Disease. 2018 , 32, 977-981 | | 34 |
| 299 | Wogonin Attenuates Isoprenaline-Induced Myocardial Hypertrophy in Mice by Suppressing the PI3K/Akt Pathway. 2018 , 9, 896 | | 19 |
| 298 | Activin A and Late Postpartum Cardiac Dysfunction Among Women With Hypertensive Disorders of Pregnancy. 2018 , 72, 188-193 | | 21 |
| 297 | Is low serum albumin concentration associated with the adverse cardiovascular events in stable coronary heart disease?. 2018 , 266, 260 | | 0 |
| 296 | Natural approaches in metabolic syndrome management. 2018 , 14, 422-441 | | 83 |
| 295 | Trends in urban/rural inequalities in cardiovascular risk bio-markers among Chinese adolescents in two decades of urbanisation: 1991-2011. 2018 , 17, 101 | | 8 |
| 294 | The Emerging Role of Biomarkers in the Diagnosis of Gestational Diabetes Mellitus. <i>Journal of Clinical Medicine</i> , 2018 , 7, | 5.1 | 32 |
| 293 | Software Tools and Approaches for Compound Identification of LC-MS/MS Data in Metabolomics. 2018 , 8, | | 253 |
| 292 | Computational analysis identifies putative prognostic biomarkers of pathological scarring in skin wounds. 2018 , 16, 32 | | 4 |
| 291 | Established and Emerging Roles of Biomarkers in Heart Failure. 2018 , 123, 614-629 | | 105 |
| 290 | Prognostic Implications of Single-Sample Confirmatory Testing for Undiagnosed Diabetes: A Prospective Cohort Study. 2018 , 169, 156-164 | | 31 |
| 289 | Molecular Coronary Plaque Imaging Using F-Fluoride. 2019 , 12, e008574 | | 24 |
| 288 | A new approach to biological modeling: Introduction to the biology of functions. 2019 , 215-254 | | |
| 287 | An Introduction to Personalized Nutrition. 2019 , 3-32 | | 2 |
| 286 | Prognostic significance of serum albumin in patients with stable coronary artery disease treated by percutaneous coronary intervention. 2019 , 14, e0219044 | | 19 |
| 285 | Atherogenic Index of Plasma: Novel Predictive Biomarker for Cardiovascular Illnesses. 2019 , 50, 285-294 | | 44 |
| 284 | First Evaluation of an Index of Low Vagally-Mediated Heart Rate Variability as a Marker of Health Risks in Human Adults: Proof of Concept. <i>Journal of Clinical Medicine</i> , 2019 , 8, | 5.1 | 20 |

| | | |
|-----|---|-------|
| 283 | Elevated serum alpha-1 antitrypsin is a major component of GlycA-associated risk for future morbidity and mortality. 2019 , 14, e0223692 | 10 |
| 282 | Association of IL-10-1082A/G polymorphism with cardiovascular disease risk: Evidence from a case-control study to an updated meta-analysis. 2019 , 7, e888 | 1 |
| 281 | Cytokines in heart failure. 2019 , 93, 63-113 | 8 |
| 280 | Somewhere over the sex differences rainbow of myocardial infarction remodeling: hormones, chromosomes, inflammasome, oh my. 2019 , 16, 933-940 | 3 |
| 279 | Point-of-care biomarker quantification enabled by sample-specific calibration. 2019 , 5, eaax4473 | 40 |
| 278 | Biomarkers in heart failure: the past, current and future. 2019 , 24, 867-903 | 48 |
| 277 | Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis. 2019 , 16, e00122 | 2 |
| 276 | Complexity and integration. A philosophical analysis of how cancer complexity can be faced in the era of precision medicine. 2019 , 9, 1 | 5 |
| 275 | Metabolomic Pattern Predicts Incident Coronary Heart Disease. 2019 , 39, 1475-1482 | 23 |
| 274 | Association between genetic variants of NOS3, TGF- β and susceptibility of diabetic nephropathy: A meta-analysis. 2019 , 21, 100573 | 1 |
| 273 | A Novel Biomarker Approach to Exploit HDL for Risk Assessment. 2019 , 73, 2146-2149 | |
| 272 | Cardiac Remodeling: The Course Towards Heart Failure-II. Diagnostic and Therapeutic Approaches. 2019 , 247-280 | |
| 271 | Biomarkers in Progressive Chronic Kidney Disease. Still a Long Way to Go. 2019 , 40, 27-39 | 8 |
| 270 | Sex differences in the association between ideal cardiovascular health and biomarkers of cardiovascular disease among adults in the United States: a cross-sectional analysis from the multiethnic study of atherosclerosis. 2019 , 9, e031414 | 13 |
| 269 | Strengths and Limitations of the Veterans Aging Cohort Study Index as a Measure of Physiologic Frailty. 2019 , 35, 1023-1033 | 10 |
| 268 | Lifetime risk of cardiometabolic mortality according to vitamin D status of middle and older-aged adults: NHANES III mortality follow-up. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019 , 186, 34-41 | 5.1 6 |
| 267 | Lab Standards: A Practical Guide for Clinicians. 2019 , 1-10 | |
| 266 | Metabolomics, Proteomics, and Genomics. 2019 , 159-170 | 3 |

| | | |
|-----|---|----|
| 265 | Future Directions in the Use of Biomarkers for Prevention of Cardiovascular Disease. 2019 , 171-177 | |
| 264 | Protein measurements in venous plasma, earlobe capillary plasma and in plasma stored on filter paper. 2019 , 566, 146-150 | 1 |
| 263 | An integrated microfluidic system with field-effect-transistor sensor arrays for detecting multiple cardiovascular biomarkers from clinical samples. 2019 , 129, 155-163 | 37 |
| 262 | Association of B-Type Natriuretic Peptide Level With Residual Kidney Function in Incident Peritoneal Dialysis Patients. 2019 , 39, 147-154 | 2 |
| 261 | Biomarkers of Potential Harm: Summary of an FDA-Sponsored Public Workshop. 2019 , 21, 3-13 | 20 |
| 260 | Serum neprilysin and the risk of death in patients with out-of-hospital cardiac arrest of non-traumatic origin. 2020 , 9, S169-S174 | 4 |
| 259 | Run, lift, or both? Associations between concurrent aerobic-muscle strengthening exercise with adverse cardiometabolic biomarkers among Korean adults. 2020 , 27, 738-748 | 11 |
| 258 | Cardiovascular risk assessment models: Have we found the perfect solution yet?. 2020 , 27, 2375-2385 | 3 |
| 257 | Favorable Changes in Biomarkers of Potential Harm to Reduce the Adverse Health Effects of Smoking in Smokers Switching to the Menthol Tobacco Heating System 2.2 for 3 Months (Part 2). 2020 , 22, 549-559 | 18 |
| 256 | Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases. 2020 , 18, 10-30 | 24 |
| 255 | Liquid Biopsies: Microvesicles in Cardiovascular Disease. 2020 , 33, 645-662 | 12 |
| 254 | Robust and multiplexed colorimetric immunoassay for cardiovascular disease biomarkers detection in serum with high specificity. 2020 , 152, 104334 | 3 |
| 253 | Recent advances of tissue-interfaced chemical biosensors. 2020 , 8, 3371-3381 | 9 |
| 252 | Inertial microfluidic cube for automatic and fast extraction of white blood cells from whole blood. 2020 , 20, 244-252 | 22 |
| 251 | Paper based point of care immunosensor for the impedimetric detection of cardiac troponin I biomarker. 2019 , 22, 6 | 29 |
| 250 | Ultraspecific analyte detection by direct kinetic fingerprinting of single molecules. 2020 , 123, 115764-115764 | 6 |
| 249 | Total Microfluidic chip for Multiplexed diagnostics (ToMMx). 2020 , 150, 111930 | 8 |
| 248 | Effects of physical inactivity in cardiovascular biomarkers. 2020 , 5, 21-21 | |

| | | |
|-----|---|----|
| 247 | EVs as Potential New Therapeutic Tool/Target in Gastrointestinal Cancer and HCC. 2020 , 12, | 11 |
| 246 | Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. 2020 , 22, 1966-1983 | 61 |
| 245 | Circulating ACE2: a novel biomarker of cardiovascular risk. 2020 , 396, 937-939 | 10 |
| 244 | Maternal and umbilical cord procalcitonin, high-sensitivity C-reactive protein, and interleukin-6 levels in preeclamptic and normotensive patients: A cross-sectional study. 2020 , 21, 218-223 | 2 |
| 243 | Prognostic Significance of Serum Albumin in Patients With Acute Coronary Syndrome. 2020 , 71, 903-908 | 6 |
| 242 | Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. 2021 , 23, 1026-1036 | 16 |
| 241 | Advances in Cardiovascular Biomarker Discovery. 2020 , 8, | 11 |
| 240 | The inflammatory markers sST2, HSP27 and hsCRP as a prognostic biomarker panel in chronic heart failure patients. 2020 , 510, 507-514 | 5 |
| 239 | Investigating Potential Risk Factors for Cardiovascular Diseases in Adult Qatari Population. 2020 , | 1 |
| 238 | Association of Exhaled Carbon Monoxide With Ideal Cardiovascular Health, Circulating Biomarkers, and Incidence of Heart Failure in the Framingham Offspring Study. 2020 , 9, e016762 | 1 |
| 237 | A review of novel biomarkers and imaging techniques for assessing the severity of chemotherapy-induced peripheral neuropathy. 2020 , 16, 1147-1158 | 2 |
| 236 | Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident Heart Failure. 2020 , 76, 1455-1465 | 15 |
| 235 | Past Sodium Intake, Contemporary Sodium Intake, and Cardiometabolic Health in Southwest Coastal Bangladesh. 2020 , 9, e014978 | 2 |
| 234 | Urinary Biomarkers: Diagnostic Tools for Monitoring Athletes' Health Status. 2020 , 17, | 6 |
| 233 | Metabonomic Responses of Grazing Yak to Different Concentrate Supplementations in Cold Season. 2020 , 10, | 5 |
| 232 | Associations of 24-Hour Urinary Sodium and Potassium Excretion with Cardiac Biomarkers: The Maastricht Study. 2020 , 150, 1413-1424 | 3 |
| 231 | Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19. 2020 , 143, 109859 | 24 |
| 230 | Heat Shock Protein 60 Antibodies Are Associated With a Risk Factor for Cardiovascular Disease in Bedridden Elderly Patients. 2020 , 7, 103 | 1 |

- 229 Analysing the nanoparticle-protein corona for potential molecular target identification. **2020**, 322, 122-136 18
- 228 Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. **2020**, 22, 1586-1597 6
- 227 Label-Free Bimetallic In Situ-Grown 3D Nickel-Foam-Supported NH-MIL-88B(FeCo)-MOF-based Impedimetric Immunosensor for the Detection of Cardiac Troponin I. **2020**, 12, 32468-32476 16
- 226 Intra-study and inter-technique validation of cardiovascular magnetic resonance imaging derived left atrial ejection fraction as a prognostic biomarker in heart failure with preserved ejection fraction. **2020**, 36, 921-928 2
- 225 A copula-based method of classifying individuals into binary disease categories using dependent biomarkers. **2020**, 29, 871-897
- 224 Soluble neprilysin: A versatile biomarker for heart failure, cardiovascular diseases and diabetic complications-A systematic review. **2020**, 72, 14-19 3
- 223 Effects of Obesity Surgery on Blood Coagulation and Fibrinolysis: A Literature Review. **2020**, 120, 579-591 10
- 222 Advances and challenges in pursuing biomarkers for obstructive sleep apnea: Implications for the cardiovascular risk. **2021**, 31, 242-249 5
- 221 Elevated Urine Leukotriene E4 Is Associated With Worse Objective Markers in Nasal Polyposis Patients. **2021**, 131, 961-966 5
- 220 Biomarkers of Pathological Dissociation: A Systematic Review. **2021**, 123, 120-202 14
- 219 Arterial function in hypertensive pregnant women. Is arterial stiffness a marker for the outcomes in pregnancy?. **2021**, 264, 118723 4
- 218 QM/MM analysis, synthesis and biological evaluation of epalrestat based mutual-prodrugs for diabetic neuropathy and nephropathy. **2021**, 108, 104556 1
- 217 Micronucleus assay for predicting coronary artery disease: A systematic review and meta-analysis. **2021**, 787, 108348 5
- 216 Electrochemistry of catalase at a liquid|liquid micro-interface array. **2021**, 138, 107694 2
- 215 Biomarkers for detection of a thrombus in the left atrial appendage: the search for the grail?. **2021**, 107, 176-177 1
- 214 Electrochemical immunosensors based on quantum dots. **2021**, 341-377
- 213 Development of Biomarkers and Point-of-Care Tests for Cerebrovascular Pathology: A Marriage of Chemistry, Biology, and Medicine. **2021**, 817-853
- 212 Advances in Quantitative Analysis of F-Sodium Fluoride Coronary Imaging. **2021**, 2021, 8849429 2

| | | | |
|-----|---|-----|----|
| 211 | Biomarkers. 2021 , 135-165 | | |
| 210 | Immunosensors Based on the Technology of Molecular Imprinted Polymers. 2021 , 117-161 | | |
| 209 | Research Progress of Nano Biotechnology-Based Sandwich Structure in Protein Immunoassay. 2021 , 11, 237-245 | | 1 |
| 208 | Depression and biomarkers of cardiovascular disease. 2021 , 239-249 | | |
| 207 | Potential effect of tropical fruits <i>Phyllanthus emblica</i> L. for the prevention and management of type 2 diabetic complications: a systematic review of recent advances. 2021 , 60, 3525-3542 | | 6 |
| 206 | Basics of clinical trials. 2021 , 483-522 | | |
| 205 | Microfluidic integrated capacitive biosensor for C-reactive protein label-free and real-time detection. 2021 , 146, 5380-5388 | | 5 |
| 204 | Biomarkers. 2021 , 31-64 | | |
| 203 | Good laboratory and experimental practices for microRNA analysis in cardiovascular research. 2021 , 395-414 | | |
| 202 | Intrinsic Frequencies of Carotid Pressure Waveforms Predict Heart Failure Events: The Framingham Heart Study. 2021 , 77, 338-346 | | 2 |
| 201 | Use of biomarkers to diagnose and manage cardiac amyloidosis. 2021 , 23, 217-230 | | 12 |
| 200 | Prognostic value of soluble suppression of tumorigenesis-2 (sST2) for cardiovascular events in coronary artery disease patients with and without diabetes mellitus. 2021 , 20, 49 | | 6 |
| 199 | European Society of Cardiology/European Society of Hypertension versus the American College of Cardiology/American Heart Association guidelines on the cut-off values for early hypertension: a microvascular perspective. <i>Scientific Reports</i> , 2021 , 11, 3473 | 4.9 | 0 |
| 198 | Cardiac Exosomes in Ischemic Heart Disease- A Narrative Review. 2021 , 11, | | 6 |
| 197 | Biomarkers for the diagnosis and management of heart failure. 2021 , 1 | | 11 |
| 196 | Machine Learning-Assisted Array-Based Detection of Proteins in Serum Using Functionalized MoS ₂ Nanosheets and Green Fluorescent Protein Conjugates. 2021 , 4, 3843-3851 | | 3 |
| 195 | Longer sleep improves cardiovascular outcomes: time to make sleep a priority. 2021 , 42, 3358-3360 | | 3 |
| 194 | Comparison of metabolic effects of the progestational androgens dimethandrolone undecanoate and 11EMNTDC in healthy men. 2021 , 9, 1526-1539 | | 1 |

| | | | |
|-----|---|-----|---|
| 193 | Point-of-care analyte quantification and digital readout via lysate-based cell-free biosensors interfaced with personal glucose monitors. | | |
| 192 | Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. 2021 , 76, 2380-2393 | | 2 |
| 191 | Further understanding of ideal cardiovascular health score metrics and cardiovascular disease. 2021 , 19, 607-617 | | 3 |
| 190 | Heart failure risk estimation based on novel biomarkers. 2021 , 21, 655-672 | | 1 |
| 189 | Biochemical markers of coronary atherosclerosis: building models and assessing their prognostic value regarding the lesion severity. 2021 , 26, 4559 | | 2 |
| 188 | Branched-chain Amino Acids and Relationship With Inflammation in Youth With Obesity: A Randomized Controlled Intervention Study. 2021 , 106, 3129-3139 | | 1 |
| 187 | Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure. 2021 , 58, 530-545 | | 2 |
| 186 | Novel insights on the role of spexin as a biomarker of obesity and related cardiometabolic disease. 2021 , 45, 2169-2178 | | 5 |
| 185 | Association between Cardiorespiratory Fitness and Circulating Proteins in 50-Year-Old Swedish Men and Women: a Cross-Sectional Study. 2021 , 7, 52 | | 1 |
| 184 | Detection of heart-fatty acid binding protein in human serum using gold nano/micro-islands and molecularly imprinted polymers. 2021 , | | |
| 183 | Sialic acid as a potential biomarker for cardiovascular disease, diabetes and cancer. <i>Biomarkers in Medicine</i> , 2021 , 15, 911-928 | 2.3 | 0 |
| 182 | The snapshot of metabolic health in evaluating micronutrient status, the risk of infection and clinical outcome of COVID-19. 2021 , 44, 173-187 | | 3 |
| 181 | The genetic architecture of plasma kynurenine includes cardiometabolic disease mechanisms associated with the SH2B3 gene. <i>Scientific Reports</i> , 2021 , 11, 15652 | 4.9 | 1 |
| 180 | Translational medicine in hereditary hemorrhagic telangiectasia. 2021 , | | 1 |
| 179 | Biomarkers in Acute Heart Failure Syndromes: An Update. <i>Current Cardiology Reviews</i> , 2021 , | 2.4 | 0 |
| 178 | Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. 2021 , 23, 1577-1596 | | 7 |
| 177 | Cardiovascular Calcification and Carotid Intima-media Thickness in Atherosclerosis. 2022 , 17-32 | | |
| 176 | Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 746382 | 5.4 | 3 |

| | | |
|-----|---|----|
| 175 | Firefighters' occupational exposure: Contribution from biomarkers of effect to assess health risks. 2021 , 156, 106704 | 8 |
| 174 | Laser-scribed graphene sensor based on gold nanostructures and molecularly imprinted polymers: Application for Her-2 cancer biomarker detection. 2021 , 347, 130556 | 8 |
| 173 | Personalized nutrition and omics technologies: current status and perspectives. 2021 , 37-71 | 0 |
| 172 | The streamlined allostatic load index is associated with perceived stress in life - findings from the MIDUS study. 2021 , 24, 404-412 | 1 |
| 171 | Optimal cholesterol treatment plans and genetic testing strategies for cardiovascular diseases. 2021 , 24, 1-25 | 3 |
| 170 | Extracellular Matrix Biomarkers of Adverse Remodeling After Myocardial Infarction. 2013 , 383-412 | 1 |
| 169 | The Meaning of Individualized Medicine—A Terminological Adjustment of a Perplexing Term. 2015 , 11-28 | 5 |
| 168 | New Ultrasound Technologies for Quantitative Assessment of Left Ventricular Function. 2015 , 377-399 | 1 |
| 167 | Implications of Arterial Stiffness. 2015 , 27-41 | 1 |
| 166 | Omics Technology. 2010 , 11-31 | 7 |
| 165 | Biomarker Discovery in Biological Fluids. 2011 , 291-326 | 4 |
| 164 | Biomarker-Guided Therapy for Chronic Heart Failure. 2016 , 63-83 | 2 |
| 163 | DYSLIPIDEMIAS. 2009 , 303-320 | 1 |
| 162 | Optical imaging for the new grammar of drug discovery. 2011 , 369, 4651-65 | 10 |
| 161 | Widespread pleiotropy confounds causal relationships between complex traits and diseases inferred from Mendelian randomization. | 13 |
| 160 | Photonic immobilization techniques used for the detection of cardiovascular disease biomarkers. 2018 , | 1 |
| 159 | Untargeted Mass Spectrometry Lipidomics identifies correlation between serum sphingomyelins and plasma cholesterol. 2019 , 18, 38 | 12 |
| 158 | Cocoa, hazelnuts, sterols and soluble fiber cream reduces lipids and inflammation biomarkers in hypertensive patients: a randomized controlled trial. 2012 , 7, e31103 | 31 |

| | | | |
|-----|---|-----|-----|
| 157 | Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. 2012 , 7, e37483 | | 521 |
| 156 | Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the heart failure in care homes (HFinCH) diagnostic accuracy study. 2013 , 8, e53560 | | 36 |
| 155 | Integrative bioinformatics analysis of genomic and proteomic approaches to understand the transcriptional regulatory program in coronary artery disease pathways. 2013 , 8, e57193 | | 9 |
| 154 | Multiple inflammatory biomarker detection in a prospective cohort study: a cross-validation between well-established single-biomarker techniques and an electrochemiluminescence-based multi-array platform. 2013 , 8, e58576 | | 22 |
| 153 | Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Studies. 2016 , 11, e0165811 | 96 | |
| 152 | Cardiac markers in five different breeds of rabbits (<i>Oryctolagus cuniculus</i> Linnaeus, 1758) used for cardiovascular research. 2016 , 36, 737-742 | | 3 |
| 151 | [Prediction of Subclinical Coronary Atherosclerosis in Patients with High and Very High Cardiovascular Risk]. 2020 , 60, 75-82 | | 1 |
| 150 | Novel Biomarkers in Cardiovascular Disease: A Review. 2010 , 2, 66 | | 1 |
| 149 | Serum cystatin C is associated with large cerebral artery stenosis in acute ischemic stroke. 2017 , 8, 67181-67188 | | 0 |
| 148 | Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease. 2016 , 4, 236 | | 51 |
| 147 | Gamma-glutamyl transferase and cardiovascular disease. 2016 , 4, 481 | | 58 |
| 146 | The Prognostic Value of Heart Type Fatty Acid Binding Protein in Patients with Suspected Acute Coronary Syndrome: A Systematic Review. <i>Current Cardiology Reviews</i> , 2017 , 13, 189-198 | 2.4 | 10 |
| 145 | Sub-chronic oral toxicity assessment (90 days) of ethanolic fraction of leaves of (<i>R. Br. ex Benn.</i>) <i>Rob.</i> in rodents: A lesser known ethnomedicinal plant from the Cholanaickan tribal community, India. 2018 , 11, 221-235 | | 1 |
| 144 | The Effects of Antiplatelet, Antithrombotic, and Thrombolytic Agents on Inflammation and Circulating Inflammatory Biomarkers. 2009 , 67-98 | | 1 |
| 143 | Role of Interleukin-18 and the Thrombus Precursor Protein in Coronary Artery Disease. 2020 , 114, 692-698 | | 3 |
| 142 | A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol. 2012 , 9, 228-36 | | 3 |
| 141 | Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer. 2014 , 20, 9759-74 | | 28 |
| 140 | Activities of Anti-Oxidative Enzymes, Catalase and Glutathione Reductase in Red Blood Cells of Patients with Coronary Artery Disease. 2007 , 2, 437-440 | | 4 |

| | | |
|-----|---|---|
| 139 | Nanomedicine: Tiny Particles and Machines, from Diagnosis to Treatment of Cardiovascular Disease, Provides Huge Achievements. 2015 , 06, 613-623 | 3 |
| 138 | Building Evidence Implicating Novel Cardiovascular Biomarkers in Obstructive Sleep Apnea. 2017 , 13, 361-362 | 2 |
| 137 | Multiple Cardiac Biomarker Testing Among Patients With Acute Dyspnea From the ICON-RELOADED Study. 2021 , | 0 |
| 136 | Dietary Concentrate Supplementation Alters Serum Metabolic Profiles Related to Energy and Amino Acid Metabolism in Grazing Simmental Heifers. 2021 , 8, 743410 | 1 |
| 135 | Point-of-Care Analyte Quantification and Digital Readout Lysate-Based Cell-Free Biosensors Interfaced with Personal Glucose Monitors. 2021 , 10, 2862-2869 | 2 |
| 134 | Requirements of a Good Biomarker: Translation into the Clinical Laboratory. 615-631 | 0 |
| 133 | Acute Coronary Syndromes. 2009 , 680-691 | |
| 132 | Heart Failure in the Era of Genomic Medicine. 2009 , 692-704 | |
| 131 | Emerging Assays. 2009 , 178-183 | |
| 130 | Biomarkers. 2010 , 225-239 | |
| 129 | Diagnosis of Heart Failure: Evidence-Based Perspective. 2010 , 353-363 | |
| 128 | Endothelial Activation Markers in Sub-clinical Atherosclerosis: Insights from Mechanism-Based Paradigms. 2011 , 179-194 | |
| 127 | Genomics and Proteomics: The Role of Contemporary Biomolecular Analysis in Advancing the Knowledge of Atherosclerotic Coronary Artery Disease. 2011 , 135-149 | |
| 126 | Circulating Endothelial Progenitor Cells: Mechanisms and Measurements. 2011 , 151-167 | |
| 125 | ???????????????? : ??????????(6.????????????????,?74????????????). 2010 , 18, 279-283 | |
| 124 | ????????????????????(6.????????????????,?74????????????). 2010 , 18, 273-278 | |
| 123 | Biomarkers in Acute Ischemic Heart Disease. 2011 , 101-112 | |
| 122 | Nanomonitor Technology and Its Applicability to Diagnosis of Cardiac Disease. 2011 , 179-199 | |

- 121 PENTRAXIN 3 : A NEW BIOMARKER OF INFLAMMATION IN ACUTE CORONARY SYNDROMES-FROM BENCH TO BEDSIDE. **2012**, 58, 293-302
- 120 The Pathophysiology of Coronary Artery Disease. **2012**, 1-28 1
- 119 Biomarkers in heart failure. **2012**, 58-75
- 118 Aging and Markers of Adverse Remodeling After Myocardial Infarction. **2013**, 487-512 4
- 117 Proteomics Toward Biomarkers Discovery and Risk Assessment. **2013**, 115-130
- 116 Proteases as Clinical Markers of Adverse Remodeling for Heart Failure in the Aging Population. **2014**, 427-458
- 115 Determination of homocysteine by lc-ms-ms with atmospheric pressure chemical ionization. **2014**, 60, 235-245 1
- 114 Stem Cell Biobanks and Long-Term Sustainability: A Swiss Working Model. **2014**, 143-153
- 113 Integration of Biomarkers with Plaque Imaging. **2014**, 203-214
- 112 New Biomarkers of Cardiovascular Disease in Diabetes. 30-57
- 111 Biomarker-Guided Therapy for Chronic Heart Failure. **2015**, 1-21
- 110 Discovery of Biomarkers Using Aptamers Evolved in Cell-SELEX Method. **2015**, 265-299
- 109 Inflammation Biomarkers and Cardiometabolic Risk. **2015**, 1-24
- 108 Role of Carotid Intima-Media Thickness in the Detection of Subclinical Atherosclerosis. **2015**, 3,
- 107 High blood pressure: An obscuring misnomer?. **2016**, 16, 713-9 3
- 106 Imagerie et spectroscopie par résonance magnétique nucléaire du muscle strié squelettique. **2016**, 34-67 1
- 105 Biological Markers in Nursing Research. **2017**, 25, 275-291 0
- 104 BIOMARKERS OF DEPRESSION: NEW CHALLENGES. **2017**, 56, 44-49

| | | |
|-----|--|---|
| 103 | Biomarkers: Population Screening and Risk-Stratification. 2018 , 323-333 | |
| 102 | Transcriptome and Epigenome Applications for Coronary Heart Disease Research. 2018 , 572-581 | |
| 101 | Cardiac Biomarkers and their Importance in the Diagnosis of Myocardial Ischemia and Acute Myocardial Infarction. 2018 , 22, 78-84 | 0 |
| 100 | The landscape of incident disease risk for the biomarker GlycA and its mortality stratification in angiography patients. | 0 |
| 99 | Elevated alpha-1 antitrypsin is a major component of GlycA-associated risk for future morbidity and mortality. | |
| 98 | MULTIMARKER DIAGNOSTIC PANELS FOR ATHEROSCLEROSIS. 2018 , 65-73 | 4 |
| 97 | Risk as a First Derivative: Using Intensive Repeated Measures and Molecular Approaches to Studying Families. 2019 , 141-158 | |
| 96 | Miyokard enfarkti ve kardiyovasküler olay gelişen hastalarda 5HT2C polimorfizminin saptanması | |
| 95 | Functional Neuroimaging Biomarkers in Migraine: Diagnostic, Prognostic and Therapeutic Implications. 2019 , 26, 6236-6252 | 2 |
| 94 | A Study on the Impact of the Novel Biochemical Parameter-Calcium Score in Preventing the Progression of the Cardiovascular Diseases to Invasive Interventions. 2020 , 66, S11-S17 | |
| 93 | Valid cardiac biomarkers. Part I. 2020 , 19, 2573 | 3 |
| 92 | Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes. 2021 , 1 | 0 |
| 91 | Perioperative management of patients with hypertension. Guidelines. 2020 , 7-33 | 1 |
| 90 | Predicting cardiovascular risk using a novel risk score in young and middle-age adults with HIV: associations with biomarkers and carotid atherosclerotic plaque. 2021 , 9564624211050335 | 0 |
| 89 | Valid cardiac biochemical markers. Part II. 2020 , 19, 2588 | 2 |
| 88 | Non-traditional risk factors and the risk of myocardial infarction in the young in the US population-based cohort. 2020 , 30, 100634 | 2 |
| 87 | Effects of antihypertensive treatment on systemic inflammation, oxidative stress and proinflammatory cytokine levels. 2021 , 11, 536-541 | 0 |
| 86 | Integrating soluble biomarkers and imaging technologies in the identification of vulnerable atherosclerotic patients. 2007 , 1, 165-73 | 3 |

| | | | |
|----|---|-----|-----|
| 85 | Systems biology in heart diseases. 2010 , 14, 10-6 | | 4 |
| 84 | Association of brain-type natriuretic protein and cardiac troponin I with incipient cardiovascular disease in chimpanzees (<i>Pan troglodytes</i>). 2011 , 61, 163-9 | | 10 |
| 83 | Markers of renal function tests. 2010 , 2, 170-3 | | 127 |
| 82 | Focus on the heart: alcohol consumption, HIV infection, and cardiovascular disease. 2010 , 33, 237-46 | | 17 |
| 81 | Obesity-related inflammation & cardiovascular disease: efficacy of a yoga-based lifestyle intervention. 2014 , 139, 822-34 | | 11 |
| 80 | The platelet-to-lymphocyte ratio as an inflammation marker in non-dipper hypertensive patients. 2015 , 19, 114-8 | | 9 |
| 79 | Adropin- A Novel Biomarker of Heart Disease: A Systematic Review Article. 2016 , 45, 1568-1576 | | 10 |
| 78 | Low Serum Adropin Levels are Associated with Coronary Slow Flow Phenomenon. 2018 , 34, 307-312 | | 4 |
| 77 | Inflammation beyond the Joints: Rheumatoid Arthritis and Cardiovascular Disease. 2018 , 2, | | 18 |
| 76 | Loggerhead sea turtle <i>Caretta caretta</i> plasma biochemistry and proteome profile modulation during recovery. 2021 , 252, 104433 | | 1 |
| 75 | Serum Albumin Level as a Predictor of Outcome in Patients Admitted to Pediatric Intensive Care Units.. 2021 , 37, e855-e860 | | 1 |
| 74 | Cardiovascular disease risk reduction with wolfberry consumption: a systematic review and meta-analysis of randomized controlled trials. 2021 , 1 | | 2 |
| 73 | Magnetic cell separation. 2022 , 193-225 | | 1 |
| 72 | Intraosseous infusion of liposome-encapsulated hemoglobin (HbV) acutely prevents hemorrhagic anemia-induced lethal arrhythmias, and its efficacy persists with preventing proarrhythmic side effects in the subacute phase of severe hemodilution model.. 2022 , | | 0 |
| 71 | Impedimetric immunosensors for detection of biomarkers. 2022 , 369-405 | | |
| 70 | Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat?. 2022 , 15, 618-623 | | 0 |
| 69 | New Candidates for Biomarkers and Drug Targets of Ischemic Stroke-A First Dynamic LC-MS Human Serum Proteomic Study.. <i>Journal of Clinical Medicine</i> , 2022 , 11, | 5.1 | 1 |
| 68 | Osteocalcin-expressing endothelial progenitor cells and serum osteocalcin forms are independent biomarkers of coronary atherosclerotic disease severity in male and female patients.. 2022 , 1 | | 2 |

| | | | |
|----|---|------|---|
| 67 | Cardiac Diagnosis with Machine Learning: A Paradigm Shift in Cardiac Care. 1-24 | | |
| 66 | Soluble CD40 receptor is a biomarker of the burden of carotid artery atherosclerosis in subjects at high cardiovascular risk.. <i>Atherosclerosis</i> , 2022 , 343, 1-9 | 3.1 | 0 |
| 65 | A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation.. <i>Journal of Personalized Medicine</i> , 2022 , 12, | 3.6 | 0 |
| 64 | Omega-3 fatty acids attenuate cardiovascular effects of short-term exposure to ambient air pollution.. <i>Particle and Fibre Toxicology</i> , 2022 , 19, 12 | 8.4 | 1 |
| 63 | MR elastography in nonalcoholic fatty liver disease: inter-center and inter-analysis-method measurement reproducibility and accuracy at 3T.. <i>European Radiology</i> , 2021 , 1 | 8 | 0 |
| 62 | Biomarkers of Inflammation and Oxidative stress in the Prediction and Management of Acute Coronary Syndrome. 3, | | |
| 61 | The interplay between exposure to PAHs and MTHFR C677T polymorphism on cardiovascular risk biomarkers in Mexican women.. <i>Environmental Science and Pollution Research</i> , 2022 , 1 | 5.1 | 0 |
| 60 | Nanomaterial-assisted microfluidics for multiplex assays.. <i>Mikrochimica Acta</i> , 2022 , 189, 139 | 5.8 | 1 |
| 59 | Emerging Biomarkers in Acute Coronary Syndromes - A Pathophysiologic Perspective.. <i>Heart Lung and Circulation</i> , 2022 , | 1.8 | 0 |
| 58 | Association of Cardiac Biomarkers with Cardiovascular Outcomes in Patients with Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study.. <i>Arthritis and Rheumatology</i> , 2022 , | 9.5 | 0 |
| 57 | A magnetic nanoparticle assisted microfluidic system for low abundance cell sorting with high recovery. <i>Micro and Nano Engineering</i> , 2022 , 100136 | 3.4 | 1 |
| 56 | Homocysteine as a marker for predicting disease severity in patients with COVID-19.. <i>Biomarkers in Medicine</i> , 2022 , | 2.3 | 4 |
| 55 | Harnessing nanotechnology for cardiovascular disease applications - a comprehensive review based on bibliometric analysis. <i>Nano Today</i> , 2022 , 44, 101453 | 17.9 | 1 |
| 54 | Effect of monthly vitamin D supplementation on cardiac biomarkers: a post-hoc analysis of a randomized controlled trial.. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2022 , 106093 | 5.1 | |
| 53 | Biomarkers of heart failure: current state of problem. <i>Innovative Medicine of Kuban</i> , 2021 , 67-72 | 0.3 | |
| 52 | Prognostic indicators for the onset of ischaemic versus haemorrhagic stroke in stable coronary artery disease.. <i>Medicine (United States)</i> , 2021 , 100, e27973 | 1.8 | |
| 51 | Synopsis of biomarkers of atheromatous plaque formation, rupture and thrombosis in the diagnosis of acute coronary syndromes.. <i>Current Cardiology Reviews</i> , 2022 , | 2.4 | 1 |
| 50 | Image_1.JPEG. 2018 , | | |

49 Image_2.JPEG. **2018**,

48 Image_3.JPEG. **2018**,

47 Image_1.TIF. **2018**,

46 A novel algorithm for cardiovascular screening using conjunctival microcirculatory parameters and blood biomarkers.. *Scientific Reports*, **2022**, 12, 6545 4.9 1

45 Clinical Applications of Artificial Intelligence in Early and Accurate Detection of Low-Concentration CVD Biomarkers. **2022**, 227-242

44 A Systematic Review and Meta-Analysis of Serum Concentrations of Ischaemia-Modified Albumin in Acute Ischaemic Stroke, Intracerebral Haemorrhage, and Subarachnoid Haemorrhage. *Biomolecules*, **2022**, 12, 653 5.9 0

43 Association between Cystatin C and Cardiac Function in Acute Myocardial Infarction Patients: A Real-World Analysis.. *Disease Markers*, **2022**, 2022, 7267937 3.2 0

42 Atherogenesis and Inflammation. **2022**, 1-20

41 Biomarkers of cardiovascular diseases. **2013**, 47, 11-19

40 Arachidonic acid metabolism and inflammatory biomarkers associated with exposure to polycyclic aromatic hydrocarbons. *Environmental Research*, **2022**, 212, 113498 7.9 0

39 Hepatocyte growth factor is associated with greater risk of extracoronary calcification: results from the multiethnic study of atherosclerosis. *Open Heart*, **2022**, 9, e001971 3 1

38 The Translation and Commercialisation of Biomarkers for Cardiovascular Disease: A Review. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 5-4

37 Review: Precision Medicine Approaches for Genetic Cardiomyopathy: Targeting Phospholamban R14del. *Current Heart Failure Reports*, 2.8 0

36 NT-proBNP Levels Influence the Prognostic Value of Mineral Metabolism Biomarkers in Coronary Artery Disease. *Journal of Clinical Medicine*, **2022**, 11, 4153 5.1

35 The Need for Individualized Risk Assessment in Cardiovascular Disease. *Journal of Personalized Medicine*, **2022**, 12, 1140 3.6 0

34 Gamma-glutamyl transpeptidase is a promising biological marker of heart failure. *Klinicist*, **2022**, 16, 12-20 3

33 Serum Concentrations of Ischaemia-Modified Albumin in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. **2022**, 11, 4205

32 Cardiovascular biomarkers in body fluids: progress and prospects in optical sensors. 0

| | | |
|----|--|---|
| 31 | Comparison between Carotid Distensibility-Based Vascular Age and Risk-Based Vascular Age in Middle-Aged Population Free of Cardiovascular Disease. 2022 , 11, 4931 | |
| 30 | Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond. 2022 , 9, 256 | 1 |
| 29 | Enzymatic degradation of bacterial cellulose derived carbon nanofibers (BC-CNF) by myeloperoxidase (MPO): Performance evaluation for biosensing. 2022 , 12, 100252 | 0 |
| 28 | MicroRNAs in cardiovascular diseases. 2022 , 307-315 | 0 |
| 27 | Complexity and Integration. 2022 , 65-88 | 0 |
| 26 | Investigation of Some Factors Affecting Homocysteine Levels. | 0 |
| 25 | Impact of Sex and Cardiovascular Risk Factors on Myocardial T1, Extracellular Volume Fraction, and T2 at 3 Tesla: Results From the Population-Based, Hamburg City Health Study. 2022 , 15, | 1 |
| 24 | Stroke and Emerging Blood Biomarkers: A Clinical Prospective. 2022 , 14, 784-803 | 5 |
| 23 | Association of Systemic Trimethyllysine with Heart Failure with Preserved Ejection Fraction and Cardiovascular Events. | 0 |
| 22 | Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology. | 2 |
| 21 | Current Nanomedicine for Targeted Vascular Disease Treatment: Trends and Perspectives. 2022 , 23, 12397 | 1 |
| 20 | Serum gamma glutamiltransferaz seviyeleri stabil koroner arter hastalarında koroner kollateral gelişiminin belirleyicisi olabilir mi?. | 0 |
| 19 | Applying multi-omics techniques to the discovery of biomarkers for acute aortic dissection. 9, | 0 |
| 18 | Relationship Between MicroRNA Signature and Arterial Stiffness in Patients With Ischemic Stroke. 2023 , 19, 28 | 0 |
| 17 | Evaluation of potential biomarkers for traditional Chinese medicine-based chronic heart failure syndromes: A case-control study. 2023 , 58, 102222 | 0 |
| 16 | Impact of Prenatal Alcohol Exposure on the Development and Myocardium of Adult Mice: Morphometric Changes, Transcriptional Modulation of Genes Related to Cardiac Dysfunction, and Antioxidant Cardioprotection. 2023 , 12, 256 | 1 |
| 15 | Growth Differentiation Factor-15 (GDF-15) is a Biological Marker in Heart Failure. 2023 , 13, 14-23 | 0 |
| 14 | The oft-overlooked cardiovascular complications of inflammatory bowel disease. 2023 , 19, 375-391 | 0 |

- 13 Effect of food intake on 143 biomarkers measured by Proseek Multiplex Inflammation I and Multiplex Organ Damage panels. ○
- 12 Mitochondrial miRNA as epigenomic signatures: Visualizing aging-associated heart diseases through a new lens. **2023**, 86, 101882 ○
- 11 A study of thyroid disorders in patients with renal disease in Karbala city in Iraq. **2023**, ○
- 10 Compositional isotemporal substitution analysis of physical activity, sedentary behaviour and cardiometabolic biomarkers in US adults: A nationally representative study. 1-10 ○
- 9 Clinical Diagnostics Ex-Vivo Based on Fluorescence. **2023**, 493-528 ○
- 8 Monocyte to HDL and Neutrophil to HDL Ratios as Potential Ischemic Stroke Prognostic Biomarkers. **2023**, 15, 301-317 ○
- 7 Surface plasmon resonance based-optical biosensor: Emerging diagnostic tool for early detection of diseases. ○
- 6 Occurrence of MTHFR C677T gene polymorphism and its association with atherogenic indices in Mexican women from San Luis Potosi, a preliminary study. ○
- 5 Occurrence of MTHFR C677T gene polymorphism and its association with atherogenic indices in Mexican women from San Luis Potosi, a preliminary study. ○
- 4 Racial/Ethnic Discrimination and Cardiometabolic Diseases: A Systematic Review. ○
- 3 Identification of Protein Biomarkers of the Dietary Approaches to Stop Hypertension Diet in Randomized Feeding Studies and Validation in an Observational Study. **2023**, 12, ○
- 2 A novel application of finite Gaussian mixture model (GMM) using real and simulated biomarkers of cardiovascular disease to distinguish adolescents with and without obesity. 1-15 ○
- 1 Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions. **2023**, 8, ○